carbamates has been researched along with Diabetes Mellitus, Type 2 in 267 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide." | 9.14 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010) |
| "To evaluate the effect of generic sofosbuvir and daclatasvir (SOF/DCV) treatment on the glycemic state and insulin resistance as well as lipid profiles of those who achieved sustained virological response (SVR) in diabetic chronic hepatitis C virus (CHC) patients." | 8.02 | Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. ( Abdel Alem, S; Abdellatif, Z; Abdo, M; Moustafa, A; Rabiee, A, 2021) |
| " However, its blood concentration has been reported to increase in combination with clopidogrel, an antiplatelet drug, and in patients with severe renal insufficiency." | 8.02 | Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency. ( Fujii, K; Hazama, Y; Kosugi, M; Miyoshi, Y; Nagata, S; Obata, Y; Takayama, K; Uehara, Y; Yamaguchi, H; Yasuda, T, 2021) |
| "In this analysis of electronic health record data from a large database in China, metformin as first-line monotherapy greatly reduced the risk of all-cause death, cardiovascular death, and heart failure in diabetes patients as compared with nonmetformin medications." | 8.02 | Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study. ( Chen, X; Chen, Y; He, S; Li, G; Qian, X; Shen, X; Xu, X; Zhang, B, 2021) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 7.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetes patients." | 7.76 | A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. ( Bao, YQ; Hu, C; Jia, WP; Lu, JY; Qin, W; Wang, CR; Xiang, KS; Yu, WH; Zhang, R, 2010) |
| "Many drugs have been reported to interact with repaglinide in patients with type 2 diabetes mellitus, resulting in hypoglycemia." | 7.74 | Severe hypoglycemia from clarithromycin-repaglinide drug interaction. ( Khamaisi, M; Leitersdorf, E, 2008) |
| "Repaglinide is an insulin secretagogue that often exhibits considerable interindividual variability in therapeutic efficacy." | 6.82 | A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients. ( Adelusi, TI; Bao, Z; Li, W; Lu, Q; Lv, D; Shang, Z; Song, J; Sun, J; Wang, T; Wang, Y; Yin, X; Zhou, X; Zhu, J, 2016) |
| "Repaglinide is an insulin secretion enhancer with a different mechanism of action to the sulphonylureas, which means it does not continuously stimulate insulin secretion." | 6.41 | [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2]. ( Rutten, GE, 2001) |
| " In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide." | 5.14 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010) |
| " However, body weight, waist circumference, fasting serum levels of insulin and C-peptide were lower and less number of patients experienced hypoglycaemia during treatment with metformin vs." | 5.12 | Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. ( Frandsen, M; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Vaag, A, 2007) |
| " We compared the effects of two insulin secretagogues, repaglinide and glyburide, known to have different efficacy on postprandial hyperglycemia, on carotid intima-media thickness (CIMT) and markers of systemic vascular inflammation in type 2 diabetic patients." | 5.11 | Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. ( Esposito, K; Giugliano, D; Marfella, R; Nappo, F, 2004) |
| "Over 13 weeks, both repaglinide and gliclazide, when combined with bedtime NPH insulin produce similar significant improvements in glycaemic control (-1%) and similar weight gain." | 5.10 | Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. ( Furlong, NJ; Hardy, KJ; Hulme, SA; O'Brien, SV, 2003) |
| "This double-blind randomized placebo-controlled parallel group study assessed the efficacy and safety (with particular regard to body weight and hypoglycemia) of repaglinide when used in a flexible mealtime dosing regimen in a situation close to everyday clinical practice." | 5.09 | Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. ( Dedov, I; Frandsen, KB; Gomis, R; Moses, RG; Schlienger, JL, 2001) |
| " One such combination regimen is repaglinide (a prandial glucose regulator that increases insulin release) plus metformin (an insulin sensitizer that inhibits hepatic glucose output, increases peripheral glucose uptake and utilization and minimizes weight gain)." | 4.84 | Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. ( Raskin, P, 2008) |
| " The sulfonyluereas, repaglinide, metformin, acarbose and the thiazolidinediones are effective in decreasing fasting plasma glucose levels, but their limitations may include adverse effects, such as weight gain and hypoglycemia, and an inability to modify some of the important comorbidities of diabetes." | 4.80 | Advances in oral therapy for type 2 diabetes. ( Davis, SN, 2000) |
| "To evaluate the effect of generic sofosbuvir and daclatasvir (SOF/DCV) treatment on the glycemic state and insulin resistance as well as lipid profiles of those who achieved sustained virological response (SVR) in diabetic chronic hepatitis C virus (CHC) patients." | 4.02 | Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. ( Abdel Alem, S; Abdellatif, Z; Abdo, M; Moustafa, A; Rabiee, A, 2021) |
| " However, its blood concentration has been reported to increase in combination with clopidogrel, an antiplatelet drug, and in patients with severe renal insufficiency." | 4.02 | Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency. ( Fujii, K; Hazama, Y; Kosugi, M; Miyoshi, Y; Nagata, S; Obata, Y; Takayama, K; Uehara, Y; Yamaguchi, H; Yasuda, T, 2021) |
| "In this analysis of electronic health record data from a large database in China, metformin as first-line monotherapy greatly reduced the risk of all-cause death, cardiovascular death, and heart failure in diabetes patients as compared with nonmetformin medications." | 4.02 | Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study. ( Chen, X; Chen, Y; He, S; Li, G; Qian, X; Shen, X; Xu, X; Zhang, B, 2021) |
| " We fed albino rats a high-fat fructose diet (HFFD) for 2 months to induce insulin resistance/type 2 diabetes and then treated the rats with ellagic acid (10 mg/kg body weight, orally) and/or repaglinide (0." | 3.85 | Estimation of ellagic acid and/or repaglinide effects on insulin signaling, oxidative stress, and inflammatory mediators of liver, pancreas, adipose tissue, and brain in insulin resistant/type 2 diabetic rats. ( Amin, MM; Arbid, MS, 2017) |
| "We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone." | 3.81 | Anakinra treatment in patients with gout and type 2 diabetes. ( Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A, 2015) |
| "Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| " The effect of food on their bioavailability is similar." | 3.78 | Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ( Kikuchi, M, 1996) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 3.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetes patients." | 3.76 | A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. ( Bao, YQ; Hu, C; Jia, WP; Lu, JY; Qin, W; Wang, CR; Xiang, KS; Yu, WH; Zhang, R, 2010) |
| "Many drugs have been reported to interact with repaglinide in patients with type 2 diabetes mellitus, resulting in hypoglycemia." | 3.74 | Severe hypoglycemia from clarithromycin-repaglinide drug interaction. ( Khamaisi, M; Leitersdorf, E, 2008) |
| "Patients with type 2 diabetes who were admitted to our hospital were enrolled in our study (n = 12)." | 2.94 | Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes. ( Fukui, M; Hasegawa, G; Hirata, A; Kadono, M; Nakajima, H; Okada, H; Okada, Y; Oyamada, H; Tanaka, M; Yamane, T, 2020) |
| " Pharmacokinetic curves were recorded at steady-state." | 2.84 | Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. ( Aarnoutse, RE; Burger, DM; Colbers, A; de Kanter, CTMM; Drenth, JPH; Smolders, EJ; Tack, CJ; van Ewijk-Beneken Kolmer, N; Velthoven-Graafland, K; Wolberink, LT, 2017) |
| " The incidences of adverse events (AEs) were 29." | 2.84 | Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. ( Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D, 2017) |
| "Objective Switching from sulfonylureas to repaglinide in patients with type 2 diabetes improves glycemic control; however, the optimal dosage has not been fully evaluated." | 2.82 | Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes. ( Aoki, K; Kamiko, K; Kamiyama, H; Nakajima, S; Shinoda, K; Taguri, M; Terauchi, Y, 2016) |
| "Repaglinide is an insulin secretagogue that often exhibits considerable interindividual variability in therapeutic efficacy." | 2.82 | A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients. ( Adelusi, TI; Bao, Z; Li, W; Lu, Q; Lv, D; Shang, Z; Song, J; Sun, J; Wang, T; Wang, Y; Yin, X; Zhou, X; Zhu, J, 2016) |
| "Repaglinide is a short-acting insulin secretagogue, which often results in considerable interindividual variability in therapeutic efficacy when widely used in a clinical setting." | 2.80 | PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus. ( Cui, YW; Guo, H; Li, W; Lu, Q; Lv, DM; Song, JF; Wang, DD; Wang, T; Wang, Y; Yin, XX; Zhang, F; Zhou, XY; Zhu, J, 2015) |
| "Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China." | 2.79 | Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. ( Liao, Y; Liu, LY; Liu, W; Ma, J; Tao, T; Wu, PH, 2014) |
| "Japanese adults with type 2 diabetes mellitus, who had been treated without sulphonylureas or glinides for >3 months, were randomly assigned to two groups to receive either 0." | 2.79 | Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus. ( Aoki, K; Kamiko, K; Kamiyama, H; Nakajima, S; Shinoda, K; Taguri, M; Terauchi, Y, 2014) |
| "Patients with type 2 diabetes are at increased susceptibility to a prolonged QT interval." | 2.79 | Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues. ( Amato, S; Baiocco, E; Curione, M; Di Bona, S; Gatti, A; Mandosi, E; Morano, S; Rossetti, M; Salvatore, S; Tarquini, G; Turinese, I; Varrenti, M, 2014) |
| "Metformin has been reported to reduce α-dicarbonyls, which are known to contribute to diabetic complications." | 2.76 | Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. ( Barto, R; Engelen, L; Ferreira, I; Gram, J; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Stehouwer, CD; Tarnow, L; Teerlink, T; Vaag, AA; Winther, K, 2011) |
| "A total of 47 newly diagnosed type 2 diabetes patients were randomized 1:1 to receive a 4-week treatment with repaglinide or gliclazide." | 2.76 | Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in. ( Bu, P; Lei, MX; Liao, EY; Luo, J; Mo, ZH; Xie, YH; Zhang, H, 2011) |
| "The aim of this research is to determine efficacy and safety of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy." | 2.76 | Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. ( Bu, R; Liu, J; Ning, G; Su, Q; Wang, W, 2011) |
| "Repaglinide was also associated with an increase in the AUC(60) and AUC(120) for insulin (+56%, +61%) and C-peptide (+41%, +36%)." | 2.76 | Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. ( Bain, SC; Bodvarsdottir, TB; Bracken, RM; Deacon, CF; Dunseath, G; Holst, JJ; Lowe, GD; Luzio, S; Prior, SL; Rumley, A; Stephens, JW; Wareham, K, 2011) |
| "Treatment with meglitinides reconstructed postprandial ghrelin secretion patterns to those of controls without diabetes." | 2.75 | Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. ( Möhlig, M; Otto, B; Pfeiffer, AF; Pivovarova, O; Rudovich, N; Spranger, J; Weickert, MO, 2010) |
| " In this study, the effects of insulin glargine (IG) in combination with repaglinide or acarbose on glycemic parameters were investigated." | 2.74 | The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. ( Duran, C; Ercan, I; Ersoy, C; Erturk, E; Guclu, M; Imamoglu, S; Kiyici, S; Selimoglu, H; Tuncel, E, 2009) |
| "The efficacy of twice-daily dosing of a repaglinide/metformin FDC tablet was non-inferior to that of three-times-daily dosing." | 2.74 | Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. ( Lewin, A; Lyness, W; Raskin, P; Reinhardt, R, 2009) |
| "Metformin/repaglinid is an efficient and safe therapeutic regime in the treatment of the type 2 DM that ensure a better control of PBG levels (Tab." | 2.74 | Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration. ( Antic, S; Dimic, D; Radenkovic, S; Velojic Golubovic, M, 2009) |
| "Weight gain was less with metformin plus biphasic insulin aspart 70/30 than with repaglinide plus biphasic insulin aspart 70/30 (difference in mean body weight between treatments -2." | 2.74 | Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. ( Frandsen, M; Hansen, BV; Lund, SS; Nielsen, BB; Parving, HH; Pedersen, O; Tarnow, L; Vaag, AA, 2009) |
| "Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study." | 2.73 | Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris. ( Betti, RT; Ferreira, BM; Gersh, BJ; Hueb, W; Lopes, N; Moffa, PJ; Ramires, JA; Uchida, AH; Wajchenberg, BL, 2007) |
| "A total of 230 Chinese patients with type 2 diabetes were enrolled in five clinical centres." | 2.73 | Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. ( Huang, L; Li, J; Li, Q; Li, Y; Liang, J; Liu, Y; Luo, R; Ni, Z; Tian, H; Wang, N; Wu, T; Yu, H, 2007) |
| "The combination of repaglinide, metformin and bedtime NPH is safe and effective and it provides better postprandial blood glucose control." | 2.73 | Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. ( Civera, M; Martínez, I; Merchante, A; Salvador, M; Sanz, J, 2008) |
| "Non-obese patients with type 2 diabetes (T2DM) are characterized by predominant defective insulin secretion." | 2.73 | Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. ( Frandsen, M; Lund, SS; Parving, HH; Pedersen, O; Smidt, UM; Tarnow, L; Vaag, AA, 2008) |
| "In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation." | 2.73 | Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. ( Frandsen, M; Gram, J; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Teerlink, T; Vaag, AA; Winther, K, 2008) |
| "Repaglinide treatment reduced fasting ADP-induced P-selectin expression compared with baseline (P = 0." | 2.72 | Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. ( Hjemdahl, P; Ostenson, CG; Wallén, NH; Yngen, M, 2006) |
| "Repaglinide was well tolerated and had no toxicity." | 2.72 | Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment. ( Cetinkalp, S; Erdogan, M; Karadeniz, M; Ozbek, M; Ozgen, AG; Saygili, F; Tuzun, M; Yilmaz, C, 2006) |
| "Repaglinide has a good safety and efficacy profile in type 2 diabetic patients complicated by renal impairment and is an appropriate treatment choice, even for individuals with more severe degrees of renal impairment." | 2.71 | Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. ( Hasslacher, C, 2003) |
| "Repaglinide was initiated at 0." | 2.71 | The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study. ( Bech, P; Gomis, R; Moses, R, 2003) |
| "Pioglitazone dosage was fixed at 30 mg per day." | 2.71 | Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. ( Gooch, B; Greco, S; Hale, PM; Hassman, DR; Jain, R; Jovanovic, L; Khutoryansky, N, 2004) |
| "Repaglinide plus acarbose treatment significantly reduced the mean increase in postprandial blood glucose levels (24." | 2.71 | Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. ( Hofmann, U; Paulwitz, O; Rosak, C, 2004) |
| "Persons with Type 2 diabetes who were poorly controlled on oral therapy were randomly assigned to monotherapy with repaglinide or combination therapy with repaglinide plus metformin." | 2.71 | The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. ( Banerji, MA; Crouse, RJ; Feinglos, MN; Goff, DC; Herrington, DM; Jovanovic, L; Lipkin, EW; Pettitt, DJ; Probstfield, JL; Reboussin, DM; Steffes, M; Summerson, J; Williamson, J, 2004) |
| "Repaglinide is an oral anti-diabetic agent that has a short duration of action, and is suitable for preventing post-prandial rises in glucose levels." | 2.71 | Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. ( Garon, J; Gerstein, HC; Joyce, C; Rolfe, A; Walter, CM, 2004) |
| "Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities." | 2.71 | Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. ( Caumo, A; Cobelli, C; Singhal, P; Taylor, R, 2005) |
| "Repaglinide is an effective oral hypoglycemic agent taken either as monotherapy or combination therapy." | 2.71 | Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. ( Abrams, Z; Lieberman, N; Shapiro, MS, 2005) |
| "The glucose lowering effect of repaglinide at a dosing level of 1." | 2.71 | [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial]. ( Li, JW; Tian, HM; Wang, JN; Yu, HL; Zhang, XX; Zhao, GZ, 2005) |
| "Sixteen diet-treated Caucasians with type 2 diabetes (mean HbA(1c) 8." | 2.71 | Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients. ( Cozma, LS; Dunseath, GJ; Luzio, SD; Owens, DR; Underwood, PM, 2005) |
| "We examined 10 patients with Type 2 diabetes in a double-blind placebo-controlled, cross-over design." | 2.71 | Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. ( Damsbo, P; Gall, MA; Hollingdal, M; Juhl, CB; Pincus, S; Pørksen, N; Schmitz, O; Sturis, J; Veldhuis, JD, 2005) |
| " After Ramadan, patients resumed their regular meal pattern and treatment dosage for 4 weeks." | 2.70 | Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. ( Mafauzy, M, 2002) |
| "To compare the effect on glycemic control and weight gain of repaglinide versus metformin combined with bedtime NPH insulin in patients with type 2 diabetes." | 2.70 | Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. ( Furlong, NJ; Hardy, KJ; Hulme, SA; O'Brien, SV, 2002) |
| " In the group of patients with severe renal dysfunction, the main pharmacokinetic finding was a longer half-life after multiple dosing." | 2.70 | Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. ( Abbasi, I; Hasslacher, C; Hatorp, V; Sattler, K; Schumacher, S; Sieber, J; Weise, D, 2001) |
| "Diet or tablet-treated patients with Type 2 diabetes (n = 256; age 40-75 years, body mass index (BMI) 20-35 kg/m2, HbA1c 4." | 2.70 | Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. ( Dejgaard, A; Kilhovd, B; Lager, I; Madsbad, S; Mustajoki, P, 2001) |
| "Repaglinide was titrated, based on capillary blood glucose, from 0." | 2.70 | Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. ( De Leeuw, IH; Van Acker, KL; Van Gaal, LF, 2001) |
| " The purpose of this pharmacodynamic study was to validate a prandial regimen of repaglinide by comparing meal-related dosing with a regimen in which the same total daily dose was divided into only two doses at morning and evening meals." | 2.70 | Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. ( Andersen, PH; Jønler, M; Lund, S; Pørksen, N; Schmitz, O, 2002) |
| "To develop a predictive population pharmacokinetic/ pharmacodynamic (PK/PD) model for repaglinide (REP), an oral hypoglycemic agent, using artificial neural networks (ANNs)." | 2.70 | Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks. ( Fossler, MJ; Haidar, SH; Hussain, AS; Johnson, SB, 2002) |
| "Repaglinide is a newly developed oral blood glucose-lowering agent that exerts its effect by stimulating insulin secretion." | 2.69 | A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. ( Landgraf, R; Wolffenbuttel, BH, 1999) |
| "Repaglinide was administered preprandially with each meal, and glyburide was administered as recommended in current labeling, i." | 2.69 | A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. ( Clauson, P; Damsbo, P; Marbury, TC; Windfeld, K, 1999) |
| "Repaglinide monotherapy was as effective as metformin monotherapy." | 2.69 | Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. ( Boyages, S; Carter, J; Colagiuri, S; Donnelly, T; Hopkins, H; Kidson, W; Moffitt, P; Moses, R; Slobodniuk, R, 1999) |
| "Glyburide was increased as necessary to 5 or 10 mg before breakfast (placebo before lunch and dinner) or to 15 mg (10 mg before breakfast, placebo before lunch, and 5 mg before dinner)." | 2.69 | Repaglinide versus glyburide: a one-year comparison trial. ( Huang, WC; Lebovitz, H; Marbury, T; Strange, P, 1999) |
| "Repaglinide is a novel, rapid-acting prandial glucose regulator." | 2.69 | Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. ( Clauson, P; Damsbo, P; Hatorp, V; Marbury, TC; Müller, PG, 1999) |
| "Repaglinide was well tolerated in a preprandial fixed-dose regimen of 1 mg or 4 mg, assigned without adjustment for clinical parameters." | 2.69 | Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. ( Dailey, G; Goldstein, BJ; Huang, WC; Jovanovic, L; Strange, P, 2000) |
| "A total of 16 Caucasian men with type 2 diabetes participated in two placebo-controlled double-blind randomized cross-over studies." | 2.69 | Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. ( Bayer, T; Ismail, I; Luzio, SD; Owens, DR, 2000) |
| "Repaglinide monotherapy was more effective in lowering HbA1c levels than troglitazone monotherapy Repaglinide/troglitazone combination therapy was effective and did not show unexpected adverse events." | 2.69 | Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. ( Berger, S; Jovanovic, L; Raskin, P; Ratner, R; Schwartz, S; Woo, V, 2000) |
| "Repaglinide was administered 15 minutes before meals (breakfast, lunch, and dinner)." | 2.69 | Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. ( Goldberg, RB; Graf, RJ; Huang, WC; Marbury, TC; Polvino, W; Schwartz, SL; Strange, P; Weston, I, 1999) |
| "Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they received either repaglinide or glibenclamide twice daily." | 2.67 | Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. ( Kruseman, AC; Menheere, PP; Müller, PG; Nijst, L; Sels, JP; Wolffenbuttel, BH, 1993) |
| "In addition, Type 2 diabetes mellitus susceptibility genes, such as KCNQ1, PAX4 and BETA2, also influence the efficacy of glinides." | 2.52 | Pharmacogenomics of glinides. ( Chen, M; Hu, C; Jia, W, 2015) |
| "A key to successful therapy for type 2 diabetes is the insight that this condition is progressive and that the need for additional agents over time is normative." | 2.49 | Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. ( Bailey, T, 2013) |
| "Meglitinide analogues are a class of oral hypoglycaemic agents that increase insulin secretion, in particular, during the early phase of insulin release." | 2.44 | Meglitinide analogues for type 2 diabetes mellitus. ( Black, C; Donnelly, P; McIntyre, L; Royle, PL; Shepherd, JP; Thomas, S, 2007) |
| "Repaglinide is an insulin secretagogue that lowers blood glucose levels in patients with T2DM." | 2.44 | Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. ( Birkeland, KI; Johansen, OE, 2007) |
| "Nateglinide is an amino acid derivative." | 2.41 | Insulin secretagogues. ( Davies, MJ, 2002) |
| "Type 2 diabetes mellitus is characterised both by impaired release of insulin and by resistance to the action of insulin." | 2.41 | Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes. ( Pørksen, N, 2002) |
| " The prandial glucose regulator repaglinide has been studied in combination with metformin (an inhibitor of hepatic glucose production), neutral protamine Hagedorn (NPH)-insulin (which has a long duration of effect, but at the risk of early hypoglycaemia and late hyperglycaemia in the dosing interval) and three thiazolidinediones (TZDs--troglitazone, rosiglitazone and pioglitazone, which stimulate nuclear receptors to increase insulin sensitivity and reduce insulin resistance) in patients whose diabetes was inadequately controlled by previous monotherapy or combination therapy." | 2.41 | Repaglinide in combination therapy. ( Moses, R, 2002) |
| "Type 2 diabetes mellitus is a progressive disorder, and although oral monotherapy is often initially successful, it is associated with a high secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia." | 2.41 | Combining sulfonylureas and other oral agents. ( Riddle, M, 2000) |
| "Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often associated with insulin resistance." | 2.41 | Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? ( Lauritzen, T; Nattrass, M, 2000) |
| "Type 2 diabetes is characterised by a progressive deterioration of the prandial insulin response, in a situation of continuing insulin resistance." | 2.41 | The importance of early insulin secretion and its impact on glycaemic regulation. ( Garber, AJ, 2000) |
| "Type 2 diabetes mellitus is a complex heterogenous metabolic disorder in which peripheral insulin resistance and impaired insulin release are the main pathogenetic factors." | 2.41 | Meglitinide analogues in the treatment of type 2 diabetes mellitus. ( Landgraf, R, 2000) |
| "Repaglinide is a novel insulin secretagogue that was developed as a prandial glucose regulator for the treatment of people with Type 2 diabetes mellitus." | 2.41 | A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. ( Moses, R, 2000) |
| "Repaglinide is an insulin secretion enhancer with a different mechanism of action to the sulphonylureas, which means it does not continuously stimulate insulin secretion." | 2.41 | [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2]. ( Rutten, GE, 2001) |
| " When multiple dosages of a drug were tested, the results of the highest approved dosage were used." | 2.41 | Oral antihyperglycemic therapy for type 2 diabetes: scientific review. ( Inzucchi, SE, 2002) |
| "Increasingly, type 2 diabetes takes a toll on public health and healthcare costs in the United States." | 2.41 | Current oral agents for type 2 diabetes. Many options, but which to choose when? ( Ahmann, AJ; Riddle, MC, 2002) |
| "Repaglinide is a novel, fast-acting prandial oral hypoglycaemic agent developed for the treatment of patients with type 2 diabetes whose disease cannot be controlled by diet and exercise alone." | 2.41 | Clinical pharmacokinetics and pharmacodynamics of repaglinide. ( Hatorp, V, 2002) |
| "Repaglinide is a novel insulin secretagogue being developed for the management of type 2 (non-insulin-dependent) diabetes mellitus." | 2.40 | Repaglinide. ( Balfour, JA; Faulds, D, 1998) |
| "In older patients with type 2 diabetes, life expectancy and the presence of microvascular complications determine the appropriate intensity of glucose control." | 2.40 | Type 2 diabetes: glycemic targets and oral therapies for older patients. ( Lardinois, CK, 1998) |
| " The implications of tailoring repaglinide treatment to meals were examined in a study where repaglinide was dosed either morning and evening, or with each main meal (i." | 2.40 | Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs. ( Owens, DR, 1998) |
| "While insulin resistance is common in older people, large numbers also have impaired insulin secretion." | 2.40 | The elderly Type 2 diabetic patient: special considerations. ( Morley, JE, 1998) |
| "Repaglinide does not cause insulin release in the absence of exogenous glucose, nor does it inhibit the biosynthesis of proinsulin." | 2.40 | Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. ( Malaisse, WJ, 1999) |
| "Repaglinide has an equivalent safety and efficacy profile to the sulphonylureas, although it is superior to glipizide in maintaining long-term glycaemic control The postprandial glucose levels are significantly lower with repaglinide compared with glibenclamide." | 2.40 | Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. ( Owens, DR, 1999) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action." | 2.40 | Pharmacologic therapy for type 2 diabetes mellitus. ( DeFronzo, RA, 1999) |
| "Repaglinide was more effective than glipizide at maintaining glycaemic control and was equivalent to glibenclamide and gliclazide on the basis of change in HbA1c." | 2.40 | Repaglinide as monotherapy in Type 2 diabetes. ( Gomis, R, 1999) |
| " The most common adverse event in the phase II studies was hypoglycaemia." | 2.40 | Preclinical and clinical studies on safety and tolerability of repaglinide. ( Schatz, H, 1999) |
| "Repaglinide is a new oral blood glucose lowering agent, a member of the carbamoylmethyl benzoic acid (CMBA) family." | 2.40 | Repaglinide--a new compound for the treatment of patients with type 2 diabetes. ( Wolffenbuttel, BH, 1999) |
| "Current agents for the treatment of Type 2 diabetes mellitus improve the metabolic profile but do not reinstate normality." | 2.40 | New agents for Type 2 diabetes. ( Bailey, CJ; Nattrass, M, 1999) |
| " This study was conducted to explore the clinical effects of repaglinide combined with exercise rehabilitation on improving the blood glucose of patients with diabetes." | 1.72 | Clinical Effects of Exercise Rehabilitation Combined with Repaglinide in the Treatment of Diabetes. ( Li, Y; Wang, X; Zhang, Y, 2022) |
| "Serious hypoglycemia is a major adverse event associated with insulin secretagogues." | 1.72 | Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. ( Bilker, WB; Brensinger, CM; Flory, JH; Hee Nam, Y; Hennessy, S; Leonard, CE, 2022) |
| "Repaglinide and metformin were complexed with amberlite resin; later resin complexed drug was encapsulated in Ethylcellulose floating microspheres." | 1.62 | Repaglinide and Metformin-Loaded Amberlite Resin-Based Floating Microspheres for the Effective Management of Type 2 Diabetes. ( Jain, AK; Jain, SK; Mishra, K; Sahu, P, 2021) |
| "Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues." | 1.51 | Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019) |
| "8% of patients treated with a combination of a sulfonylurea and insulin knew this side effect of the OAD." | 1.48 | Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management. ( Harsch, IA; Kaestner, RH; Konturek, PC, 2018) |
| "Metformin was the most common initial treatment in all countries." | 1.46 | Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study. ( Bezemer, ID; Bianchini, E; Blin, P; Hall, GC; Hammar, N; Heintjes, EM; Herings, RMC; Lapi, F; Lassalle, R; Overbeek, JA; Prieto-Alhambra, D, 2017) |
| " We aimed to systematically screen for drugs that interact with the five most commonly used secretagogues-glipizide, glyburide, glimepiride, repaglinide, and nateglinide-to cause serious hypoglycemia." | 1.46 | Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. ( Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017) |
| " The rate of adverse events was 86." | 1.43 | Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin. ( Hanafusa, T; Hotta, N; Ioriya, K; Kageyama, S; Kaku, K; Kawamori, R, 2016) |
| "34 patients with suspected MODY, negative for mutations in the GCK, HNF1α, HNF4α, HNF1β and PDX1 genes, were screened by next generation sequencing (NGS)." | 1.43 | Clinical and molecular characterization of a novel INS mutation identified in patients with MODY phenotype. ( Artuso, R; Barni, F; Braccesi, G; Casalini, E; Giglio, S; Guasti, M; Lenzi, L; Piccini, B; Toni, S, 2016) |
| "In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae." | 1.42 | Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015) |
| "The treatment of newly diagnosed type 2 diabetes mellitus is diverse, with no clear consensus regarding the initial drug regimen or dosing to achieve optimal glycemic control." | 1.42 | Getting to goal in newly diagnosed type 2 diabetes using combination drug "subtraction therapy". ( George, TM; Jennings, AS; Jennings, JS; Lovett, AJ, 2015) |
| "Type 2 diabetes is characterised by insulin resistance and deficiencywhich explains the multitude of molecules developed for its treatment." | 1.40 | [New medications for patients with type 2 diabetes]. ( Meillet, L, 2014) |
| " plus single-dose insulin glargine regimen was safe for low-risk type 2 diabetic patients who insisted on fasting during Ramadan." | 1.35 | Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. ( Bakiner, O; Bozkirli, E; Demirag, NG; Ertorer, ME; Tutuncu, NB, 2009) |
| "Treatment with nateglinide or repaglinide was characterized by a higher incidence of hypoglycaemia at the beginning of treatment." | 1.35 | Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. ( Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L, 2009) |
| "Repaglinide (RPG) is an oral hypoglycemic agent with excellent bioavailability (90-98%) and a short plasma half-life (2-6 h)." | 1.35 | Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ( Jain, S; Saraf, S, 2009) |
| "For patients with type 2 diabetes, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) currently recommend a glycosylated hemoglobin (HbA(1c) ) target of <7%, and the British Medical Association (BMA) Quality and Outcomes Framework recommends an HbA(1c) target of >or=7." | 1.35 | Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. ( Moses, RG, 2008) |
| "In this fasting sample of patients with type 2 diabetes, glimepiride, repaglinide, and insulin glargine did not produce significant changes in glucose and lipid parameters." | 1.34 | A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. ( Bayram, F; Cesur, M; Corapcioglu, D; Emral, R; Gonen, S; Gursoy, A; Kamel, N; Ozduman, M; Tonyukuk, V; Uysal, AR; Yilmaz, AE, 2007) |
| "Type 2 diabetes mellitus is a chronic disease with potentially devastating long-term complications." | 1.33 | Oral agents in managing diabetes mellitus in children and adolescents. ( Jacobson-Dickman, E; Levitsky, L, 2005) |
| "Repaglinide is a prandial glucose regulator indicated for management of type 2 diabetes." | 1.33 | Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. ( Marshall, V; Shakir, S; Wilton, L, 2006) |
| "Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion." | 1.32 | Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. ( Abrahamson, MJ, 2004) |
| "Repaglinide is a novel oral antidiabetic agent, marking the development of a new class of drugs for type 2 diabetes." | 1.31 | Repaglinide: a novel oral antidiabetic agent. ( Nattrass, M, 2000) |
| "Repaglinide is a suitable agent for first-line monotherapy in patients whose glucose metabolism cannot be optimally controlled by increasing physical activity and appropriate dietary measures." | 1.31 | [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients]. ( Landgraf, R, 2000) |
| " However, these trials employed fixed dosing and mealtime regimens, so repaglinide was not used as intended." | 1.31 | Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes. ( Bauer, C; Dieken, ML; Frank, M; Landgraf, R, 2000) |
| "Repaglinide (NovoNorm) is an antidiabetic oral agent of the new glinide class with insulinotropic activity." | 1.31 | [Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)]. ( Scheen, AJ, 2001) |
| "Repaglinide was more potent than glibenclamide in stimulating insulin release from perifused mouse islets (EC50 29 vs." | 1.30 | Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. ( Brand, CL; Carr, RD; Fuhlendorff, J; Kofod, H; MacKay, P; Rolin, B; Rorsman, P; Shymko, R, 1998) |
| " Pharmacokinetic profiles, including area under the curve (AUC), log(AUC), maximal concentration (Cmax), log(Cmax), time to maximal concentration (Tmax), and half-life (T(1/2)), were determined at completion of the single- and multiple-dose regimens (days 1 and 9, respectively)." | 1.30 | Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes. ( Hatorp, V; Huang, WC; Strange, P, 1999) |
| "During type 2 diabetes mellitus, repaglinide is the first fast-acting oral antidiabetic drug able to stimulate endogenous insulin secretion during meal by mimicking physiological insulin secretion pattern." | 1.30 | [Mechanisms of action of repaglinide at a cellular level]. ( Thomsen, MK, 1999) |
| "The natural history of type 2 diabetes involves a progressive pancreatic beta-cell dysfunction leading to quantitative, qualitative and/or temporal abnormalities in insulin secretion and insensitivity to insulin action which predominates in muscles." | 1.30 | [Insulin secretion and repaglinide]. ( Owens, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 43 (16.10) | 18.2507 |
| 2000's | 139 (52.06) | 29.6817 |
| 2010's | 72 (26.97) | 24.3611 |
| 2020's | 13 (4.87) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 3 |
| Wang, X | 3 |
| Zhang, Y | 2 |
| Okada, H | 1 |
| Tanaka, M | 1 |
| Hasegawa, G | 1 |
| Nakajima, H | 1 |
| Kadono, M | 1 |
| Okada, Y | 2 |
| Hirata, A | 1 |
| Oyamada, H | 1 |
| Yamane, T | 1 |
| Fukui, M | 1 |
| Abdel Moneim, A | 1 |
| Suleiman, HA | 1 |
| Mahmoud, B | 2 |
| Mabrouk, D | 1 |
| Zaky, MY | 1 |
| Pishdad, R | 2 |
| Pishdad, P | 2 |
| Pishdad, GR | 2 |
| Gnesin, F | 1 |
| Thuesen, ACB | 1 |
| Kähler, LKA | 1 |
| Madsbad, S | 2 |
| Hemmingsen, B | 2 |
| Panahi, Y | 1 |
| Abdo, M | 1 |
| Rabiee, A | 1 |
| Abdellatif, Z | 1 |
| Abdel Alem, S | 1 |
| Moustafa, A | 1 |
| Jain, AK | 1 |
| Sahu, P | 1 |
| Mishra, K | 1 |
| Jain, SK | 1 |
| Ipsen, EØ | 1 |
| Madsen, KS | 1 |
| Chi, Y | 1 |
| Pedersen-Bjergaard, U | 1 |
| Richter, B | 1 |
| Metzendorf, MI | 1 |
| Takayama, K | 1 |
| Fujii, K | 1 |
| Yamaguchi, H | 1 |
| Miyoshi, Y | 1 |
| Uehara, Y | 1 |
| Nagata, S | 1 |
| Obata, Y | 1 |
| Kosugi, M | 1 |
| Hazama, Y | 1 |
| Yasuda, T | 1 |
| He, S | 1 |
| Qian, X | 1 |
| Chen, Y | 1 |
| Shen, X | 1 |
| Zhang, B | 1 |
| Chen, X | 3 |
| Xu, X | 1 |
| Li, G | 1 |
| Hee Nam, Y | 1 |
| Brensinger, CM | 2 |
| Bilker, WB | 2 |
| Flory, JH | 1 |
| Leonard, CE | 2 |
| Hennessy, S | 2 |
| Overbeek, JA | 1 |
| Heintjes, EM | 1 |
| Prieto-Alhambra, D | 1 |
| Blin, P | 1 |
| Lassalle, R | 1 |
| Hall, GC | 1 |
| Lapi, F | 1 |
| Bianchini, E | 1 |
| Hammar, N | 1 |
| Bezemer, ID | 1 |
| Herings, RMC | 1 |
| Smolders, EJ | 1 |
| Colbers, A | 1 |
| de Kanter, CTMM | 1 |
| Velthoven-Graafland, K | 1 |
| Wolberink, LT | 1 |
| van Ewijk-Beneken Kolmer, N | 1 |
| Drenth, JPH | 1 |
| Aarnoutse, RE | 1 |
| Tack, CJ | 2 |
| Burger, DM | 1 |
| Areosa Sastre, A | 1 |
| Vernooij, RW | 1 |
| González-Colaço Harmand, M | 1 |
| Martínez, G | 1 |
| Tanaka, K | 1 |
| Mori, H | 1 |
| Torimoto, K | 1 |
| Arao, T | 1 |
| Tanaka, Y | 1 |
| Ballmann, M | 1 |
| Hubert, D | 1 |
| Assael, BM | 1 |
| Staab, D | 1 |
| Hebestreit, A | 1 |
| Naehrlich, L | 1 |
| Nickolay, T | 1 |
| Prinz, N | 1 |
| Holl, RW | 1 |
| Shang, Z | 2 |
| Han, F | 1 |
| Zhou, X | 3 |
| Bao, Z | 3 |
| Zhu, J | 3 |
| Wang, T | 6 |
| Lu, Q | 5 |
| Du, L | 1 |
| Li, W | 5 |
| Lv, D | 3 |
| Yin, X | 3 |
| Omori, K | 1 |
| Nomoto, H | 1 |
| Nakamura, A | 1 |
| Takase, T | 1 |
| Cho, KY | 1 |
| Ono, K | 1 |
| Manda, N | 1 |
| Kurihara, Y | 1 |
| Aoki, S | 1 |
| Atsumi, T | 1 |
| Miyoshi, H | 1 |
| Wang, LC | 2 |
| Fang, FS | 2 |
| Gong, YP | 2 |
| Yang, G | 1 |
| Li, CL | 2 |
| Rathish, D | 1 |
| Senavirathna, I | 1 |
| Jayasumana, C | 1 |
| Agampodi, S | 1 |
| Siribaddana, S | 1 |
| Harsch, IA | 1 |
| Kaestner, RH | 1 |
| Konturek, PC | 1 |
| Huang, HK | 1 |
| Yeh, JI | 1 |
| Chen, C | 1 |
| Yin, D | 1 |
| Zhao, F | 1 |
| Zhao, Y | 1 |
| Jin, Y | 1 |
| Hussein, HA | 1 |
| Allam, AS | 1 |
| Moaty, ASA | 1 |
| Katsuyama, H | 1 |
| Hiraishi, C | 1 |
| Hakoshima, Y | 1 |
| Yanai, H | 1 |
| Niphakis, MJ | 1 |
| Cognetta, AB | 1 |
| Chang, JW | 1 |
| Buczynski, MW | 1 |
| Parsons, LH | 1 |
| Byrne, F | 1 |
| Burston, JJ | 1 |
| Chapman, V | 1 |
| Cravatt, BF | 1 |
| Wang, Y | 5 |
| Zhao, L | 1 |
| Huang, Q | 6 |
| Peng, Y | 1 |
| Bailey, T | 1 |
| Lv, DM | 2 |
| Song, JF | 2 |
| Gao, X | 1 |
| Zhang, F | 2 |
| Guo, H | 2 |
| Yin, XX | 2 |
| Maruthur, NM | 1 |
| Gribble, MO | 1 |
| Bennett, WL | 1 |
| Bolen, S | 1 |
| Wilson, LM | 1 |
| Balakrishnan, P | 1 |
| Sahu, A | 1 |
| Bass, E | 1 |
| Kao, WH | 1 |
| Clark, JM | 1 |
| Li, J | 2 |
| Tian, H | 2 |
| Huang, W | 1 |
| Li, L | 2 |
| Vitale, A | 1 |
| Cantarini, L | 1 |
| Rigante, D | 1 |
| Bardelli, M | 1 |
| Galeazzi, M | 1 |
| Ma, J | 1 |
| Liu, LY | 1 |
| Wu, PH | 1 |
| Liao, Y | 1 |
| Tao, T | 1 |
| Liu, W | 1 |
| Yin, J | 1 |
| Deng, H | 1 |
| Qin, S | 1 |
| Tang, W | 1 |
| Zeng, L | 2 |
| Zhou, B | 1 |
| Kamiyama, H | 2 |
| Aoki, K | 2 |
| Nakajima, S | 2 |
| Shinoda, K | 2 |
| Kamiko, K | 2 |
| Taguri, M | 2 |
| Terauchi, Y | 2 |
| Zhou, XY | 1 |
| Wang, DD | 1 |
| Cui, YW | 1 |
| Mogensen, UM | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Schramm, TK | 1 |
| Vaag, A | 2 |
| Scheller, NM | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, G | 1 |
| Køber, L | 1 |
| Mennecart, M | 1 |
| Mondon, K | 1 |
| Malherbe, C | 1 |
| Constans, T | 1 |
| Meillet, L | 1 |
| Huang, Y | 1 |
| Abdelmoneim, AS | 2 |
| Light, P | 1 |
| Qiu, W | 1 |
| Simpson, SH | 2 |
| Chen, M | 2 |
| Hu, C | 6 |
| Jia, W | 6 |
| Jiang, DQ | 1 |
| Li, MX | 1 |
| Jennings, AS | 1 |
| Lovett, AJ | 1 |
| George, TM | 1 |
| Jennings, JS | 1 |
| Ferrannini, E | 1 |
| DeFronzo, RA | 2 |
| Zhang, R | 5 |
| Jiang, F | 3 |
| Wang, J | 1 |
| Peng, D | 1 |
| Yan, J | 1 |
| Wang, S | 3 |
| Bao, Y | 3 |
| Zhao, S | 1 |
| Mugabo, Y | 1 |
| Ballentine, G | 1 |
| Attane, C | 1 |
| Iglesias, J | 1 |
| Poursharifi, P | 1 |
| Zhang, D | 1 |
| Nguyen, TA | 1 |
| Erb, H | 1 |
| Prentki, R | 1 |
| Peyot, ML | 1 |
| Joly, E | 1 |
| Tobin, S | 1 |
| Fulton, S | 1 |
| Brown, JM | 1 |
| Madiraju, SR | 1 |
| Prentki, M | 1 |
| Kawamori, R | 1 |
| Kaku, K | 3 |
| Hanafusa, T | 1 |
| Ioriya, K | 1 |
| Kageyama, S | 1 |
| Hotta, N | 1 |
| Nishimura, A | 1 |
| Usui, S | 1 |
| Kumashiro, N | 1 |
| Uchino, H | 1 |
| Yamato, A | 1 |
| Yasuda, D | 1 |
| Nagasawa, K | 1 |
| Okubo, M | 1 |
| Mori, Y | 1 |
| Hirose, T | 1 |
| Piccini, B | 1 |
| Artuso, R | 1 |
| Lenzi, L | 1 |
| Guasti, M | 1 |
| Braccesi, G | 1 |
| Barni, F | 1 |
| Casalini, E | 1 |
| Giglio, S | 1 |
| Toni, S | 1 |
| Song, J | 1 |
| Sun, J | 1 |
| Adelusi, TI | 1 |
| Lee, YC | 1 |
| Chang, CH | 1 |
| Dong, YH | 1 |
| Lin, JW | 1 |
| Wu, LC | 1 |
| Hwang, JS | 1 |
| Chuang, LM | 1 |
| Amin, MM | 1 |
| Arbid, MS | 1 |
| Han, X | 1 |
| Chiang, C | 1 |
| Xu, W | 1 |
| Mu, Y | 1 |
| Zhao, J | 1 |
| Zhu, D | 1 |
| Ji, Q | 1 |
| Zhou, Z | 1 |
| Yao, B | 1 |
| Mao, A | 1 |
| Engel, SS | 1 |
| Zhao, B | 1 |
| Bi, Y | 1 |
| Ran, X | 1 |
| Lu, J | 2 |
| Ji, L | 1 |
| Yang, W | 1 |
| Weng, J | 1 |
| He, YY | 1 |
| Shao, XY | 1 |
| Wang, CR | 3 |
| Lu, JX | 1 |
| Bao, YQ | 3 |
| Jia, WP | 3 |
| Xiang, KS | 3 |
| Chisalita, SI | 1 |
| Lindström, T | 1 |
| Eson Jennersjö, P | 1 |
| Paulsson, JF | 1 |
| Westermark, GT | 1 |
| Olsson, AG | 1 |
| Arnqvist, HJ | 1 |
| Kalliokoski, A | 1 |
| Neuvonen, M | 1 |
| Neuvonen, PJ | 1 |
| Niemi, M | 1 |
| Bakiner, O | 1 |
| Ertorer, ME | 1 |
| Bozkirli, E | 1 |
| Tutuncu, NB | 1 |
| Demirag, NG | 1 |
| Li, C | 1 |
| Xia, J | 1 |
| Zhang, G | 1 |
| Wang, L | 1 |
| Derosa, G | 3 |
| Salvadeo, SA | 1 |
| D'Angelo, A | 1 |
| Ferrari, I | 1 |
| Mereu, R | 1 |
| Palumbo, I | 1 |
| Maffioli, P | 1 |
| Randazzo, S | 1 |
| Cicero, AF | 1 |
| Duran, C | 1 |
| Tuncel, E | 1 |
| Ersoy, C | 1 |
| Ercan, I | 1 |
| Selimoglu, H | 1 |
| Kiyici, S | 1 |
| Guclu, M | 1 |
| Erturk, E | 1 |
| Imamoglu, S | 1 |
| Vlckova, V | 1 |
| Cornelius, V | 1 |
| Kasliwal, R | 1 |
| Wilton, L | 2 |
| Shakir, SA | 1 |
| Raskin, P | 6 |
| Lewin, A | 2 |
| Reinhardt, R | 2 |
| Lyness, W | 2 |
| Jankovec, Z | 1 |
| Lacigova, S | 1 |
| Dimic, D | 1 |
| Velojic Golubovic, M | 1 |
| Antic, S | 1 |
| Radenkovic, S | 1 |
| Davis, SN | 1 |
| Zhao, T | 1 |
| Qiu, Y | 1 |
| Su, M | 1 |
| Lund, SS | 5 |
| Tarnow, L | 5 |
| Frandsen, M | 4 |
| Nielsen, BB | 1 |
| Hansen, BV | 1 |
| Pedersen, O | 5 |
| Parving, HH | 5 |
| Vaag, AA | 4 |
| Gunduz, M | 1 |
| Argikar, UA | 1 |
| Baeschlin, D | 1 |
| Ferreira, S | 1 |
| Hosagrahara, V | 1 |
| Harriman, S | 1 |
| Yu, M | 3 |
| Xu, XJ | 3 |
| Yin, JY | 5 |
| Wu, J | 4 |
| Gong, ZC | 4 |
| Ren, HY | 1 |
| Sheng, FF | 2 |
| Zhou, HH | 6 |
| Liu, ZQ | 7 |
| Xu, L | 1 |
| Shen, J | 2 |
| Ran, J | 1 |
| Wang, M | 1 |
| Yan, L | 1 |
| Cheng, H | 1 |
| Fu, Z | 1 |
| Rudovich, N | 1 |
| Möhlig, M | 1 |
| Otto, B | 1 |
| Pivovarova, O | 1 |
| Spranger, J | 1 |
| Weickert, MO | 1 |
| Pfeiffer, AF | 2 |
| Longo, R | 1 |
| Qin, W | 2 |
| Lu, JY | 2 |
| Yu, WH | 2 |
| Wu, CZ | 1 |
| Pei, D | 1 |
| Hsieh, AT | 1 |
| Wang, K | 1 |
| Lin, JD | 1 |
| Lee, LH | 1 |
| Chu, YM | 1 |
| Hsiao, FC | 1 |
| Pei, C | 1 |
| Hsia, TL | 1 |
| Dai, XP | 5 |
| Pei, Q | 3 |
| Dong, M | 3 |
| Zhou, ZG | 1 |
| Huang, X | 1 |
| Deng, CS | 1 |
| Jain, S | 1 |
| Saraf, S | 1 |
| Meneilly, GS | 1 |
| Engelen, L | 1 |
| Ferreira, I | 1 |
| Gram, J | 2 |
| Winther, K | 2 |
| Teerlink, T | 2 |
| Barto, R | 1 |
| Stehouwer, CD | 3 |
| Schalkwijk, CG | 3 |
| Yu, W | 1 |
| Wang, C | 1 |
| Tang, S | 1 |
| Xiang, K | 1 |
| Zhang, H | 1 |
| Bu, P | 1 |
| Xie, YH | 1 |
| Luo, J | 1 |
| Lei, MX | 3 |
| Mo, ZH | 1 |
| Liao, EY | 1 |
| Rojas, P | 1 |
| Sánchez, L | 1 |
| Santos, A | 1 |
| Góõmez, MP | 1 |
| Blanco, H | 1 |
| Laguna, JJ | 1 |
| Qu, J | 2 |
| Lei, GH | 2 |
| Lu, HB | 2 |
| Liu, YZ | 1 |
| Oriot, P | 1 |
| Hermans, MP | 1 |
| Selvais, P | 1 |
| Buysschaert, M | 1 |
| de la Tribonnière, X | 1 |
| Wang, W | 1 |
| Bu, R | 1 |
| Su, Q | 1 |
| Liu, J | 1 |
| Ning, G | 1 |
| Stephens, JW | 1 |
| Bodvarsdottir, TB | 1 |
| Wareham, K | 1 |
| Prior, SL | 1 |
| Bracken, RM | 1 |
| Lowe, GD | 1 |
| Rumley, A | 1 |
| Dunseath, G | 1 |
| Luzio, S | 1 |
| Deacon, CF | 1 |
| Holst, JJ | 1 |
| Bain, SC | 1 |
| Hasenbank, SE | 1 |
| Seubert, JM | 1 |
| Brocks, DR | 1 |
| Light, PE | 1 |
| Scott, LJ | 1 |
| Zhou, BT | 1 |
| Zhou, G | 1 |
| Jarnert, C | 1 |
| Kalani, M | 1 |
| Rydén, L | 1 |
| Böhm, F | 1 |
| Se, YM | 1 |
| Sun, ZX | 1 |
| Nie, SD | 1 |
| Zeng, XM | 1 |
| Khamaisi, M | 2 |
| Guo, Y | 1 |
| Jiang, TJ | 1 |
| Li, Q | 2 |
| Tang, SS | 1 |
| del Pozo-Fernández, C | 1 |
| Pardo-Ruiz, C | 1 |
| Sánchez-Botella, C | 1 |
| Blanes-Castañer, V | 1 |
| López-Menchero, R | 1 |
| Gisbert-Sellés, C | 1 |
| Sánchez-Jodar, C | 1 |
| Alvarez-Avellán, L | 1 |
| Curione, M | 1 |
| Di Bona, S | 1 |
| Amato, S | 1 |
| Turinese, I | 1 |
| Tarquini, G | 1 |
| Gatti, A | 1 |
| Mandosi, E | 1 |
| Rossetti, M | 1 |
| Varrenti, M | 1 |
| Salvatore, S | 1 |
| Baiocco, E | 1 |
| Morano, S | 1 |
| Rahmi, RM | 1 |
| Uchida, AH | 2 |
| Rezende, PC | 1 |
| Lima, EG | 1 |
| Garzillo, CL | 1 |
| Favarato, D | 1 |
| Strunz, CM | 1 |
| Takiuti, M | 1 |
| Girardi, P | 1 |
| Hueb, W | 2 |
| Kalil Filho, R | 1 |
| Ramires, JA | 2 |
| Cozma, LS | 3 |
| Luzio, SD | 4 |
| Dunseath, GJ | 2 |
| Langendorg, KW | 1 |
| Pieber, T | 1 |
| Owens, DR | 6 |
| Mafauzy, M | 1 |
| Furlong, NJ | 2 |
| Hulme, SA | 2 |
| O'Brien, SV | 2 |
| Hardy, KJ | 2 |
| Davies, MJ | 2 |
| Matsuda, M | 1 |
| Parhofer, KG | 1 |
| Göke, B | 1 |
| Tankova, T | 1 |
| Koev, D | 1 |
| Dakovska, L | 1 |
| Kirilov, G | 1 |
| Hasslacher, C | 2 |
| Pørksen, N | 3 |
| Vergès, B | 1 |
| Moses, R | 7 |
| Mugellini, A | 2 |
| Ciccarelli, L | 2 |
| Crescenzi, G | 2 |
| Fogari, R | 2 |
| Bech, P | 1 |
| Gomis, R | 3 |
| Klaff, L | 1 |
| McGill, J | 2 |
| South, SA | 1 |
| Hollander, P | 1 |
| Khutoryansky, N | 4 |
| Hale, PM | 4 |
| Ramsdell, JW | 1 |
| Braunstein, SN | 1 |
| Stephens, JM | 1 |
| Bell, CF | 1 |
| Botteman, MF | 1 |
| Devine, ST | 1 |
| Stockl, K | 1 |
| Vanderplas, AM | 1 |
| Nicklasson, L | 2 |
| Tentolouris, N | 1 |
| Kolia, M | 1 |
| Tselepis, AD | 1 |
| Perea, D | 1 |
| Kitsou, E | 1 |
| Kyriaki, D | 1 |
| Tambaki, AP | 1 |
| Karabina, SP | 1 |
| Sala, C | 1 |
| Fragoulopoulos, E | 1 |
| Katsilambros, N | 1 |
| Blicklé, JF | 1 |
| Yoshioka, K | 1 |
| Yoshida, T | 1 |
| Yoshikawa, T | 1 |
| Baron, MA | 1 |
| Malik, T | 1 |
| Trence, DL | 1 |
| Jovanovic, L | 4 |
| Hassman, DR | 2 |
| Gooch, B | 1 |
| Jain, R | 1 |
| Greco, S | 1 |
| Kellerer, M | 1 |
| Jakob, S | 1 |
| Linn, T | 1 |
| Haslbeck, M | 1 |
| Abrahamson, MJ | 1 |
| Rizzo, MR | 3 |
| Barbieri, M | 2 |
| Grella, R | 3 |
| Passariello, N | 2 |
| Barone, M | 1 |
| Paolisso, G | 4 |
| Kølendorf, K | 1 |
| Eriksson, J | 1 |
| Birkeland, KI | 2 |
| Kjellström, T | 1 |
| Hreidarsson, AB | 1 |
| Saad, MF | 1 |
| Cappleman, JM | 1 |
| Kaye, W | 1 |
| Plosker, GL | 1 |
| Figgitt, DP | 1 |
| Rosenstock, J | 1 |
| Madder, RD | 1 |
| Brazinsky, SA | 1 |
| Farrell, J | 1 |
| Esposito, K | 1 |
| Giugliano, D | 1 |
| Nappo, F | 1 |
| Marfella, R | 1 |
| Rudovich, NN | 1 |
| Leyck Dieken, MG | 1 |
| Rochlitz, H | 1 |
| Palmer, AJ | 1 |
| Roze, S | 1 |
| Lammert, M | 1 |
| Valentine, WJ | 1 |
| Minshall, ME | 1 |
| Gall, MA | 2 |
| Spinas, GA | 1 |
| Rosak, C | 1 |
| Hofmann, U | 1 |
| Paulwitz, O | 1 |
| Reboussin, DM | 1 |
| Goff, DC | 1 |
| Lipkin, EW | 1 |
| Herrington, DM | 1 |
| Summerson, J | 1 |
| Steffes, M | 1 |
| Crouse, RJ | 1 |
| Feinglos, MN | 2 |
| Probstfield, JL | 1 |
| Banerji, MA | 1 |
| Pettitt, DJ | 1 |
| Williamson, J | 1 |
| Sari, R | 1 |
| Balci, MK | 1 |
| Akbas, SH | 1 |
| Avci, B | 1 |
| Gerstein, HC | 1 |
| Garon, J | 1 |
| Joyce, C | 1 |
| Rolfe, A | 1 |
| Walter, CM | 1 |
| Ionescu-Tîrgovişte, C | 1 |
| Guja, C | 1 |
| Ioacără, S | 1 |
| Dumitrescu, D | 1 |
| Tomescu, I | 1 |
| Nan, DN | 1 |
| Hernández, JL | 1 |
| Fernández-Ayala, M | 1 |
| Carrascosa, M | 1 |
| Blackburn, GL | 1 |
| Singhal, P | 1 |
| Caumo, A | 1 |
| Cobelli, C | 1 |
| Taylor, R | 1 |
| Manzella, D | 1 |
| Abbatecola, AM | 1 |
| Nybäck-Nakell, A | 1 |
| von Heijne, M | 1 |
| Adamson, U | 1 |
| Lins, PE | 1 |
| Landstedt-Hallin, L | 1 |
| Shapiro, MS | 1 |
| Abrams, Z | 1 |
| Lieberman, N | 1 |
| López-García, F | 1 |
| Borrás, J | 1 |
| Verdú, C | 1 |
| Salazar, VR | 1 |
| Ruiz, JA | 1 |
| Sales, J | 1 |
| Lucena, MI | 1 |
| Andrade, RJ | 1 |
| Li, JW | 1 |
| Tian, HM | 1 |
| Yu, HL | 1 |
| Zhang, XX | 1 |
| Zhao, GZ | 1 |
| Wang, JN | 1 |
| Underwood, PM | 1 |
| Maaravi, Y | 1 |
| Stessman, J | 1 |
| Malaisse, WJ | 4 |
| Panelo, A | 1 |
| Wing, JR | 1 |
| Hollingdal, M | 1 |
| Sturis, J | 1 |
| Damsbo, P | 5 |
| Pincus, S | 1 |
| Veldhuis, JD | 1 |
| Schmitz, O | 2 |
| Juhl, CB | 1 |
| Jacobson-Dickman, E | 1 |
| Levitsky, L | 1 |
| Yngen, M | 1 |
| Ostenson, CG | 1 |
| Hjemdahl, P | 1 |
| Wallén, NH | 1 |
| Anwar, A | 1 |
| Azmi, KN | 1 |
| Hamidon, BB | 1 |
| Khalid, BA | 1 |
| Marshall, V | 1 |
| Shakir, S | 1 |
| Cesur, M | 1 |
| Corapcioglu, D | 1 |
| Gursoy, A | 1 |
| Gonen, S | 1 |
| Ozduman, M | 1 |
| Emral, R | 1 |
| Uysal, AR | 1 |
| Tonyukuk, V | 1 |
| Yilmaz, AE | 1 |
| Bayram, F | 1 |
| Kamel, N | 1 |
| Papa, G | 1 |
| Fedele, V | 1 |
| Fioravanti, M | 1 |
| Leotta, C | 1 |
| Solerte, SB | 1 |
| Purrello, F | 1 |
| Napoli, A | 1 |
| Ciampa, F | 1 |
| Colatrella, A | 1 |
| Fallucca, F | 1 |
| Gersh, BJ | 1 |
| Betti, RT | 1 |
| Lopes, N | 1 |
| Moffa, PJ | 1 |
| Ferreira, BM | 1 |
| Wajchenberg, BL | 1 |
| Mollar-Puchades, MA | 1 |
| Martin-Cortes, A | 1 |
| Perez-Calvo, A | 1 |
| Diaz-Garcia, C | 1 |
| Ozbek, M | 1 |
| Erdogan, M | 1 |
| Karadeniz, M | 1 |
| Cetinkalp, S | 1 |
| Ozgen, AG | 1 |
| Saygili, F | 1 |
| Yilmaz, C | 1 |
| Tuzun, M | 1 |
| Radtke, M | 1 |
| Kollind, M | 1 |
| Qvigstad, E | 1 |
| Grill, V | 1 |
| Smidt, UM | 3 |
| Thaware, PK | 1 |
| Tringham, JR | 1 |
| Howe, J | 1 |
| Jarvis, J | 1 |
| Johnston, V | 1 |
| Kitchener, DL | 1 |
| Skinner, TC | 1 |
| McNally, PG | 1 |
| Lawrence, IG | 1 |
| Black, C | 1 |
| Donnelly, P | 1 |
| McIntyre, L | 1 |
| Royle, PL | 1 |
| Shepherd, JP | 1 |
| Thomas, S | 1 |
| Krentz, AJ | 1 |
| Wang, N | 1 |
| Wu, T | 1 |
| Liu, Y | 1 |
| Ni, Z | 1 |
| Yu, H | 1 |
| Liang, J | 1 |
| Luo, R | 1 |
| Huang, L | 1 |
| Civera, M | 1 |
| Merchante, A | 1 |
| Salvador, M | 1 |
| Sanz, J | 1 |
| Martínez, I | 1 |
| Johansen, OE | 1 |
| Moses, RG | 2 |
| Leitersdorf, E | 1 |
| Wolffenbuttel, BH | 3 |
| Nijst, L | 1 |
| Sels, JP | 1 |
| Menheere, PP | 1 |
| Müller, PG | 3 |
| Kruseman, AC | 1 |
| Kikuchi, M | 1 |
| Ladrière, L | 2 |
| Malaisse-Lagae, F | 2 |
| Fuhlendorff, J | 2 |
| Rorsman, P | 1 |
| Kofod, H | 1 |
| Brand, CL | 1 |
| Rolin, B | 1 |
| MacKay, P | 1 |
| Shymko, R | 1 |
| Carr, RD | 1 |
| Laghmich, A | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Balfour, JA | 1 |
| Faulds, D | 1 |
| Goldberg, RB | 3 |
| Einhorn, D | 1 |
| Lucas, CP | 1 |
| Rendell, MS | 1 |
| Huang, WC | 5 |
| Strange, P | 6 |
| Brodows, RG | 1 |
| Lardinois, CK | 1 |
| Morley, JE | 1 |
| Landgraf, R | 5 |
| Hatorp, V | 4 |
| Clauson, P | 2 |
| Marbury, TC | 3 |
| Windfeld, K | 1 |
| Slobodniuk, R | 1 |
| Boyages, S | 1 |
| Colagiuri, S | 1 |
| Kidson, W | 1 |
| Carter, J | 1 |
| Donnelly, T | 1 |
| Moffitt, P | 1 |
| Hopkins, H | 1 |
| Marbury, T | 1 |
| Lebovitz, H | 1 |
| Bilo, HJ | 1 |
| Schatz, H | 2 |
| Luna, B | 1 |
| Hughes, AT | 1 |
| Smits, P | 1 |
| Quillen, DM | 2 |
| Kuritzky, L | 2 |
| Samraj, GP | 1 |
| Dailey, G | 1 |
| Goldstein, BJ | 1 |
| Brown, DL | 1 |
| Brillon, D | 1 |
| Kolaczynski, JW | 1 |
| Larmore, SS | 1 |
| Thomsen, MK | 1 |
| Owens, D | 2 |
| Nattrass, M | 3 |
| Bailey, CJ | 1 |
| Riddle, M | 1 |
| Ismail, I | 1 |
| Bayer, T | 1 |
| Berger, S | 1 |
| Schwartz, S | 1 |
| Woo, V | 1 |
| Ratner, R | 1 |
| Füchtenbusch, M | 1 |
| Standl, E | 1 |
| Massi-Benedetti, M | 1 |
| Lauritzen, T | 1 |
| Garber, AJ | 1 |
| Frank, M | 1 |
| Bauer, C | 1 |
| Dieken, ML | 1 |
| Frandsen, KB | 1 |
| Schlienger, JL | 1 |
| Dedov, I | 1 |
| Blackburn, G | 1 |
| Kock, M | 1 |
| Quast, U | 1 |
| Schumacher, S | 1 |
| Abbasi, I | 1 |
| Weise, D | 1 |
| Sattler, K | 1 |
| Sieber, J | 1 |
| Laws, A | 1 |
| Pratley, RE | 1 |
| Foley, JE | 1 |
| Dunning, BE | 1 |
| Kilhovd, B | 1 |
| Lager, I | 1 |
| Mustajoki, P | 1 |
| Dejgaard, A | 1 |
| Boccuzzi, SJ | 1 |
| Wogen, J | 1 |
| Fox, J | 1 |
| Sung, JC | 1 |
| Shah, AB | 1 |
| Kim, J | 1 |
| Schwartz, SL | 1 |
| Graf, RJ | 1 |
| Polvino, W | 1 |
| Weston, I | 1 |
| Schade, DS | 1 |
| Grodsky, GM | 1 |
| Van Gaal, LF | 1 |
| Van Acker, KL | 1 |
| De Leeuw, IH | 1 |
| Scheen, AJ | 1 |
| Rutten, GE | 1 |
| Calvo Romero, JM | 1 |
| Lima Rodríguez, EM | 1 |
| de Luis, DA | 1 |
| Aller, R | 1 |
| Cuellar, L | 1 |
| Terroba, C | 1 |
| Ovalle, H | 1 |
| Izaola, O | 1 |
| Romero, E | 1 |
| Culy, CR | 1 |
| Jarvis, B | 1 |
| Dornhorst, A | 1 |
| Inzucchi, SE | 1 |
| Lund, S | 1 |
| Andersen, PH | 1 |
| Jønler, M | 1 |
| Nelson, G | 1 |
| Haidar, SH | 1 |
| Johnson, SB | 1 |
| Fossler, MJ | 1 |
| Hussain, AS | 1 |
| Ahmann, AJ | 1 |
| Riddle, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentric, Randomized, Open Label Study on Comparison of Pancreatic Beta Cell Recovery and Preservation in Type 2 Diabetic Patients Treated With DPP-4 Inhibitor (Vildagliptin) and Metformin[NCT02853630] | Phase 4 | 203 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus[NCT00679939] | Phase 4 | 226 participants (Actual) | Interventional | 2008-04-21 | Completed | ||
| [NCT00396851] | 100 participants | Interventional | 2007-01-31 | Not yet recruiting | |||
| Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes[NCT00099866] | Phase 3 | 570 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes[NCT00138567] | Phase 3 | 530 participants | Interventional | 2005-01-31 | Completed | ||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus[NCT03010683] | 60 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes[NCT00373178] | Phase 4 | 100 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Double Blind Comparison Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics With Metformin[NCT01001962] | Phase 4 | 1,054 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects[NCT00327015] | Phase 3 | 1,306 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control[NCT00103857] | Phase 3 | 1,208 participants (Actual) | Interventional | 2005-03-17 | Completed | ||
| [NCT00035568] | Phase 4 | 0 participants | Interventional | 2002-02-28 | Completed | ||
| A Multicenter, Register-based, Randomized, Controlled Trial Comparing Dapagliflozin With Metformin Treatment in Early Stage Type 2 Diabetes Patients by Assessing Mortality and Macro- and Microvascular Complications[NCT03982381] | Phase 4 | 2,067 participants (Actual) | Interventional | 2019-09-05 | Active, not recruiting | ||
| Restoring Insulin Secretion Adult Medication Study[NCT01779362] | Phase 3 | 267 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)[NCT01126580] | Phase 3 | 807 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).[NCT00994682] | Phase 4 | 176 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment[NCT00708175] | Phase 4 | 156 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)[NCT00015626] | Phase 2 | 300 participants | Interventional | Completed | |||
| [NCT00276497] | Phase 1 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance[NCT00306826] | Phase 4 | 120 participants | Interventional | Withdrawn (stopped due to financial support withdrawn) | |||
| Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282] | Phase 2 | 184 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Actos Now for Prevention of Diabetes (ACT NOW)[NCT00220961] | Phase 3 | 602 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study)[NCT01006018] | 3 participants (Actual) | Interventional | 2011-07-31 | Terminated (stopped due to Unanticipated delays due to sterilization/stabilization testing of GLP-1.) | |||
| Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT[NCT00352287] | Phase 4 | 60 participants | Interventional | 2003-03-31 | Completed | ||
| Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631] | 70 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation in Subjects With Impaired Glucose Tolerance[NCT00470262] | 27 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| A Drug-drug Interaction Study Between the Novel Anti-hepatitis c Virus (HCV) Agent Daclatasvir and The Antidiabetic Agent Metformin in Healthy Volunteers[NCT02565862] | Phase 1 | 20 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Open Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes Mellitus[NCT00662714] | Phase 3 | 73 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| The Effect of a Checklist on the Education of Simulated Patients During Insulin Initiation: a Randomized Controlled Trial[NCT02266303] | 100 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | |||
| A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Ty[NCT01709305] | Phase 4 | 5,570 participants (Actual) | Interventional | 2012-11-08 | Completed | ||
| Repaglinide and Metformin Combination Tablet (NN4440) in a TID Regimen Compared to a BID Regimen and BID Avandamet in Subjects With Type 2 Diabetes: A Twenty-Six Week, Open-Label, Multicenter, Randomized, Parallel Group Trial to Investigate Efficacy and S[NCT00399711] | Phase 3 | 560 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control Wit[NCT00118963] | Phase 4 | 102 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A 16-week, Open-label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients[NCT00819741] | Phase 4 | 433 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790] | Phase 4 | 119 participants (Actual) | Interventional | 2018-10-02 | Completed | ||
| Multi-centre, Multinational, Open-labelled, Randomised, Parallel, Controlled Trial in Type 2 Diabetic Subjects Inadequately Controlled on Repaglinide, to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime NPH Insulin Versus Twice Daily N[NCT01562561] | Phase 3 | 213 participants (Actual) | Interventional | 2001-06-01 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) in Healthy Mexican Volunteers[NCT01437800] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) After a High Fat Diet, in Healthy Mexican Volunteers[NCT01437813] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy[NCT00941161] | Phase 4 | 28 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Baseline. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
| Intervention | millimeters (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -0.120 |
| Metformin in DB Period; Metformin in OL Period | -0.040 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
| Intervention | mg/cm^3 (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 7.901 |
| Metformin in DB Period; Metformin in OL Period | -5.025 |
Cortical thickness was measured by QCT. Change from Baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
| Intervention | millimeters (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -0.082 |
| Metformin in DB Period; Metformin in OL Period | -0.048 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
| Intervention | mg/cm^3 (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -12.424 |
| Metformin in DB Period; Metformin in OL Period | -10.244 |
Cortical thickness was measured by QCT. Change from baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
| Intervention | millimeters (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -0.117 |
| Metformin in DB Period; Metformin in OL Period | -0.087 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
| Intervention | mg/cm^3 (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -4.555 |
| Metformin in DB Period; Metformin in OL Period | -7.553 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-posterior is the upper and back section of the FN. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
| Intervention | mg/cm^3 (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -8.007 |
| Metformin in DB Period; Metformin in OL Period | -7.006 |
Cortical thickness was measured by QCT. Change from baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
| Intervention | millimeters (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -0.95 |
| Metformin in DB Period; Metformin in OL Period | -0.067 |
AASC levels were measured from blood samples. AASC is the amount of free calcium circulating in the blood and calcium is required for good bone health. Change from Week 52 was calculated as the Week 76 value minus the Week 52 value and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | millimoles per Liter (mmol/L) (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 0.01 |
| Metformin in DB Period; Metformin in OL Period | 0.00 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | millimeters (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 0.09 |
| Metformin in DB Period; Metformin in OL Period | 0.01 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | mg/cm^3 (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 20.15 |
| Metformin in DB Period; Metformin in OL Period | -10.73 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | millimeters (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -0.08 |
| Metformin in DB Period; Metformin in OL Period | 0.07 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | mg/cm^3 (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 15.48 |
| Metformin in DB Period; Metformin in OL Period | -17.59 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | millimeters (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 0.11 |
| Metformin in DB Period; Metformin in OL Period | -0.13 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | mg/cm^3 (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 5.19 |
| Metformin in DB Period; Metformin in OL Period | -6.24 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | millimeters (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 0.18 |
| Metformin in DB Period; Metformin in OL Period | -0.05 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | mg/cm^3 (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 9.30 |
| Metformin in DB Period; Metformin in OL Period | -4.92 |
FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Change in FN BMD at Week 52 was only analyzed within the Rosiglitazone arm. (NCT00679939)
Timeframe: Baseline and Week 52
| Intervention | percent change (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -1.24 |
FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline and Week 76+10 days
| Intervention | percent change (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -1.91 |
| Metformin in DB Period; Metformin in OL Period | 0.31 |
FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Week 52+10 days to Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Week 52+10 days)/BMD at Week 52+10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52+10 days and Week 76+10 days
| Intervention | percent change (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -0.07 |
| Metformin in DB Period; Metformin in OL Period | -0.02 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 3.12 |
| Metformin in DB Period; Metformin in OL Period | 1.56 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | -1.48 |
| Metformin in DB Period; Metformin in OL Period | 2.04 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 14.02 |
| Metformin in DB Period; Metformin in OL Period | -13.65 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 32.42 |
| Metformin in DB Period; Metformin in OL Period | -7.80 |
BMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) |
|---|---|
| Rosiglitazone in DB Period; Metformin in OL Period | 3.53 |
| Metformin in DB Period; Metformin in OL Period | -2.11 |
AASC levels were measured from blood samples. AASC is the amount of free calcium circulating in the blood and calcium is required for good bone health. Change from baseline was calculated as the Week 52or Week 76 value minus the baseline value and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | millimoles per Liter (mmol/L) (Mean) | |
|---|---|---|
| Week 52, n=73, 83 | Week 76, n=64, 75 | |
| Metformin in DB Period; Metformin in OL Period | 0.03 | 0.04 |
| Rosiglitazone in DB Period; Metformin in OL Period | 0.01 | 0.03 |
Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | percent change (Number) | |||||
|---|---|---|---|---|---|---|
| Week 52, GM - SE, n=61, 65 | Week 52, GM, n=61, 65 | Week 52, GM + SE, n=61, 65 | Week 76, GM - SE, n=55, 58 | Week 76, GM, n=55, 58 | Week 76, GM + SE, n=55, 58 | |
| Metformin in DB Period; Metformin in OL Period | -15.9 | -12.2 | -8.4 | -12.5 | -8.9 | -5.2 |
| Rosiglitazone in DB Period; Metformin in OL Period | -27.9 | -24.7 | -21.4 | -21.3 | -18.1 | -14.6 |
BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | percent change (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 52, GM - SE, BSAP, n=78, 84 | Week 52, GM, BSAP, n=78, 84 | Week 52, GM + SE, BSAP, n=78, 84 | Week 76, GM - SE, BSAP, n=64, 77 | Week 76, GM, BSAP, n=64, 77 | Week 76, GM + SE, BSAP, n=64, 77 | Week 52, GM - SE, P1NP, n=76, 83 | Week 52, GM, P1NP, n=76, 83 | Week 52, GM + SE, P1NP, n=76, 83 | Week 76 GM - SE, P1NP, n=63, 75 | Week 76, GM, P1NP, n=63, 75 | Week 76, GM + SE, P1NP, n=63, 75 | |
| Metformin | -29.7 | -27.3 | -24.8 | -26.7 | -24.3 | -21.8 | -16.5 | -13.3 | -9.9 | -14.5 | -10.5 | -6.4 |
| Rosiglitazone | -15.2 | -12.3 | -9.3 | -18.7 | -15.9 | -12.9 | 5.0 | 9.0 | 13.3 | -11.2 | -6.9 | -2.4 |
CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | percent change (Number) | |||||
|---|---|---|---|---|---|---|
| Week 52, GM - SE, n=77, 84 | Week 52, GM, n=77, 84 | Week 52, GM + SE, n=77, 84 | Week 76, GM - SE, n=63, 77 | Week 76, GM, n=63, 77 | Week 76, GM + SE, n=63, 77 | |
| Metformin in DB Period; Metformin in OL Period | -7.8 | -2.3 | 3.7 | -4.5 | 2.6 | 10.3 |
| Rosiglitazone in DB Period; Metformin in OL Period | 11.3 | 18.1 | 25.4 | -19.5 | -13.1 | -6.1 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (orWeek 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 0.64 | 0.39 |
| Rosiglitazone in DB Period; Metformin in OL Period | -6.05 | -3.59 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | Week 52, Trabecular, n=32, 35 | Week 52, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 1.26 | 930.71 | 0.85 | 0.54 | 37.81 | -0.63 |
| Rosiglitazone in DB Period; Metformin in OL Period | -4.35 | -161.59 | -1.85 | -0.29 | 81.29 | 1.45 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | -1.27 | -0.11 |
| Rosiglitazone in DB Period; Metformin in OL Period | 0.47 | -1.46 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 1.74 | 282.16 | 1.14 | 0.01 | 13.54 | -1.17 |
| Rosiglitazone in DB Period; Metformin in OL Period | -4.11 | -84.08 | -3.42 | -3.11 | 24.46 | -1.32 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 0.58 | 0.91 | -0.20 | -0.61 | 2.27 | -1.60 |
| Rosiglitazone in DB Period; Metformin in OL Period | -3.72 | -1.83 | -1.00 | -2.13 | -1.05 | -0.46 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days(or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 5.05 | -4.78 |
| Rosiglitazone in DB Period; Metformin in OL Period | -13.45 | -4.23 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 daysor Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days(or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN. (NCT00679939)
Timeframe: Baseline, Week 52 plus 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | -0.58 | 2.82 | -0.25 | -2.45 | 3.98 | -1.49 |
| Rosiglitazone in DB Period; Metformin in OL Period | -6.56 | 3.59 | -1.91 | -4.97 | -0.85 | -0.93 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100% (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31,30 | |
| Metformin in DB Period; Metformin in OL Period | 1.00 | -1.50 |
| Rosiglitazone in DB Period; Metformin in OL Period | -20.48 | -3.52 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days orWeek 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | -0.03 | 5.57 | -0.66 | 1.07 | 10.24 | -1.30 |
| Rosiglitazone in DB Period; Metformin in OL Period | -10.26 | 2.77 | -3.76 | -4.21 | 2.37 | -1.65 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by QCT. BMD by QCT is the 2-dimensional volume that mimics the DXA measurement for the same region. Percent change from Baseline at Week 52 + 30 days orWeek 76 + 30 days was calculated as (BMD at Week 52 + 30 days (orWeek 76 + 30 days) minus BMD at baseline)/BMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 52 + 30 days; Femoral neck (FN), n=32, 35 | Week 52 + 30 days; Total hip (TH), n=32, 35 | Week 52 + 30 days; Trochanter (Tro.), n=32, 35 | Week 52+30 days; Intertrochanter (Inter.),n=32, 35 | Week 76+30 days; Femoral neck (FN), n=31, 30 | Week 76 + 30 days; TH, n=31, 30 | Week 76 + 30 days; Tro., n=31, 30 | Week 76 + 30 days; Inter., n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 0.09 | 0.09 | -0.23 | 0.77 | -1.52 | -0.32 | -1.28 | 0.30 |
| Rosiglitazone in DB Period; Metformin in OL Period | -2.39 | -3.39 | -4.53 | -3.36 | -1.98 | -2.11 | -2.86 | -1.66 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline and Week 52
| Intervention | percent change (Mean) | |||
|---|---|---|---|---|
| Femoral neck, n=52, 54 | Total hip, n=52, 54 | Trochanter, n=52, 54 | Lumbar spine, n=51, 53 | |
| Metformin in DB Period; Metformin in OL Period | 0.72 | -0.38 | -0.78 | 0.12 |
| Rosiglitazone in DB Period; Metformin in OL Period | -1.24 | -0.77 | -0.21 | -1.21 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Baseline at Week 52 + 10 days or Week 76 + 10 days was calculated as (BMD at Week 52 + 10 days (or Week 76 + 10 days ) minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 10 days, and Week 76 + 10 days
| Intervention | percent change (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 52 + 10 days; Femoral neck (FN), n=70, 78 | Week 52 + 10 days; Total hip (TH), n=70, 78 | Week 52 + 10 days; Trochanter (Tro.), n=70, 78 | Week 52 + 10 days; Lumbar spine (LS), n=70, 76 | Week 76 + 10 days; FN, n=65, 70 | Week 76 + 10 days; TH, n=65, 70 | Week 76 + 10 days; Tro., n=65, 70 | Week 76 + 10 days; LS, n=65, 71 | |
| Metformin in DB Period; Metformin in OL Period | 0.22 | -0.72 | -1.04 | 0.04 | 0.31 | -0.83 | -1.35 | 0.85 |
| Rosiglitazone in DB Period; Metformin in OL Period | -1.47 | -1.62 | -1.45 | -1.41 | -1.91 | -1.70 | -2.14 | -1.24 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (BMD at Week 52 + 30 days (or Week 76 + 30 days) minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 52 + 30 days; Femoral neck (FN), n=77, 83 | Week 52 + 30 days; Total hip (TH), n=77, 83 | Week 52 + 30 days; Trochanter (Tro.), n=77, 83 | Week 52 + 30 days; Lumbar spine (LS), n=79, 81 | Week 76 + 30 days; FN, n=66, 74 | Week 76 + 30 days; TH, n=66, 74 | Week 76 + 30 days; Tro., n=66, 74 | Week 76 + 30 days; LS, n=66, 72 | |
| Metformin in DB Period; Metformin in OL Period | 0.24 | -0.72 | -1.01 | 0.11 | 0.29 | -0.68 | -0.96 | 1.13 |
| Rosiglitazone in DB Period; Metformin in OL Period | -1.59 | -1.79 | -1.83 | -1.60 | -2.05 | -1.79 | -2.53 | -1.15 |
Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | percent change (Number) | |||||
|---|---|---|---|---|---|---|
| Week 52, GM - SE, n=64, 71 | Week 52, GM, n=64, 71 | Week 52, GM + SE, n=64, 71 | Week 76, GM - SE, n=56, 64 | Week 76, GM, n=56, 64 | Week 76, GM + SE, n=56, 64 | |
| Metformin in DB Period; Metformin in OL Period | -25.9 | -22.0 | -17.8 | -26.2 | -20.8 | -15.0 |
| Rosiglitazone in DB Period; Metformin in OL Period | -16.5 | -12.0 | -7.2 | -28.8 | -23.1 | -17.0 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 2.18 | -0.22 | 0.99 | 1.88 | 0.27 | 0.79 |
| Rosiglitazone in DB Period; Metformin in OL Period | -3.47 | -4.26 | -0.76 | -0.92 | -3.09 | 0.41 |
Volumetric (v)BMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. vBMD is the 3-dimensional density of a region of bone. Cortical bone is dense bone. Trabecular bone is spongy bone. Integral bone is the sum of cortical and trabecular bone measurements. Cortical thickness is the width of the cortical shell. Percent change from Baseline was calculated as (vBMD at Week 52+30 days (or Week 76+30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 52 + 30 days; Integral, n=32, 35 | Week 52 + 30 days; Trabecular, n=32, 35 | Week 52 + 30 days; Cortical, n=32, 35 | Week 76 + 30 days; Integral, n=31, 30 | Week 76 + 30 days; Trabecular, n=31, 30 | Week 76 + 30 days; Cortical, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 0.99 | 0.21 | 0.52 | 0.85 | 0.70 | 0.50 |
| Rosiglitazone in DB Period; Metformin in OL Period | -3.60 | -3.63 | -0.54 | -1.70 | -2.66 | 0.23 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | 0.01 | 0.67 | -0.18 | -0.93 | 0.92 | -0.64 |
| Rosiglitazone in DB Period; Metformin in OL Period | -4.80 | -3.43 | -1.26 | -2.88 | -2.42 | -0.49 |
BMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
| Intervention | percent change (Mean) | |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31, 30 | |
| Metformin in DB Period; Metformin in OL Period | -1.72 | -3.91 |
| Rosiglitazone in DB Period; Metformin in OL Period | -6.71 | -5.15 |
Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | -7.7 | -3.2 | 1.5 |
| Rosiglitazone in DB Period; Metformin in OL Period | -4.7 | 0.1 | 5.1 |
BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | |||||
|---|---|---|---|---|---|---|
| GM - SE, BSAP, n=64, 76 | GM, BSAP, n=64, 76 | GM + SE, BSAP, n=64, 76 | GM - SE, P1NP, n=63, 76 | GM, P1NP, n=63, 76 | GM + SE, P1NP, n=63, 76 | |
| Metformin in DB Period; Metformin in OL Period | 4.3 | 8.0 | 11.8 | 3.2 | 7.0 | 11.0 |
| Rosiglitazone in DB Period; Metformin in OL Period | -5.6 | -2.0 | 1.8 | -15.8 | -12.4 | -9.0 |
CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | 2.2 | 8.4 | 14.9 |
| Rosiglitazone in DB Period; Metformin in OL Period | -31.2 | -26.7 | -21.9 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| Integral | Trabecular | Cortical | |
| Metformin in DB Period; Metformin in OL Period | 0.38 | 260.13 | -1.64 |
| Rosiglitazone in DB Period; Metformin in OL Period | 5.05 | -90.60 | 3.68 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| Integral | Trabecular | Cortical | |
| Metformin in DB Period; Metformin in OL Period | -1.87 | 161.81 | -2.50 |
| Rosiglitazone in DB Period; Metformin in OL Period | 1.47 | -39.81 | 2.67 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| Integral | Trabecular | Cortical | |
| Metformin in DB Period; Metformin in OL Period | -1.37 | 2.21 | -1.30 |
| Rosiglitazone in DB Period; Metformin in OL Period | 2.21 | 0.27 | 1.03 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| Integral | Trabecular | Cortical | |
| Metformin in DB Period; Metformin in OL Period | -1.81 | 6.63 | -1.28 |
| Rosiglitazone in DB Period; Metformin in OL Period | 2.96 | -2.78 | 1.19 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| Integral | Trabecular | Cortical | |
| Metformin in DB Period; Metformin in OL Period | 0.52 | -11.69 | -0.94 |
| Rosiglitazone in DB Period; Metformin in OL Period | 8.29 | 36.05 | 2.17 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by QCT. BMD by QCT is the 2-dimensional volume that mimics the DXA measurement for the same region. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | |||
|---|---|---|---|---|
| percent change | Total hip | Trochanter | Intertrochanter | |
| Metformin in DB Period; Metformin in OL Period | -1.39 | -0.18 | -0.91 | -0.25 |
| Rosiglitazone in DB Period; Metformin in OL Period | 0.95 | 1.61 | 1.81 | 2.05 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Week 52 + 10 days toat Week 76 + 10 days was calculated as (BMD at Week 76 + 10 days minus BMD at Week 52 + 10 days)/BMD at Week 52 + 10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 10 days and Week 76 + 10 days
| Intervention | percent change (Mean) | |||
|---|---|---|---|---|
| Femoral neck, n=56, 62 | Total hip, n=56, 62 | Trochanter, n=56, 62 | Lumbar spine, n=55, 62 | |
| Metformin in DB Period; Metformin in OL Period | -0.02 | -0.13 | -0.68 | 1.03 |
| Rosiglitazone in DB Period; Metformin in OL Period | -0.07 | 0.40 | -0.02 | 0.26 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | |||
|---|---|---|---|---|
| Femoral neck, n=64, 73 | Total hip, n=64, 73 | Trochanter, n=64, 73 | Lumbar spine, n=65, 70 | |
| Metformin in DB Period; Metformin in OL Period | -0.25 | -0.27 | -0.47 | 0.90 |
| Rosiglitazone in DB Period; Metformin in OL Period | -0.27 | 0.00 | -0.17 | 0.54 |
Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | -1.7 | 4.3 | 10.7 |
| Rosiglitazone in DB Period; Metformin in OL Period | -13.2 | -7.4 | -1.3 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| percent change | Trabecular | Cortical | |
| Metformin in DB Period; Metformin in OL Period | -0.46 | 1.21 | -0.27 |
| Rosiglitazone in DB Period; Metformin in OL Period | 2.83 | 1.16 | 1.29 |
Volumetric (v)BMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. vBMD is the 3-dimensional density of a region of bone. Cortical bone is dense bone. Trabecular bone is spongy bone. Integral bone is the sum of cortical and trabecular bone measurements. Cortical thickness is the width of the cortical shell. Percent change from Week 52 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/ vBMD at Week 52 + 30 days x 100% and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| Integral | Trabecular | Cortical | |
| Metformin in DB Period; Metformin in OL Period | -0.20 | 1.15 | -0.06 |
| Rosiglitazone in DB Period; Metformin in OL Period | 2.24 | 0.90 | 0.94 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| percent change | Trabecular | Cortical | |
| Metformin in DB Period; Metformin in OL Period | -0.90 | 0.95 | -0.65 |
| Rosiglitazone in DB Period; Metformin in OL Period | 2.22 | 1.07 | 0.78 |
Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | percent change (Number) | |||||
|---|---|---|---|---|---|---|
| Week 52, GM - SE, n=74, 82 | Week 52, GM, n=74, 82 | Week 52, GM + SE, n=74, 82 | Week 76, GM - SE, n=64, 75 | Week 76, GM, n=64, 75 | Week 76, GM + SE, n=64, 75 | |
| Metformin in DB Period; Metformin in OL Period | 2.5725 | 6.266 | 10.0934 | -1.9532 | 2.478 | 7.1093 |
| Rosiglitazone in DB Period; Metformin in OL Period | -9.9964 | -5.940 | 1.7006 | -0.3232 | 3.687 | 7.8593 |
Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | percent change (Number) | |||||
|---|---|---|---|---|---|---|
| Week 52, GM - SE, n=74, 82 | Week 52, GM, n=74, 82 | Weel 52, GM + SE, n=74, 82 | Week 76, GM - SE, n=64, 76 | Week 76, GM, n=64, 76 | Week 76, GM + SE, n=64, 76 | |
| Metformin in DB Period; Metformin in OL Period | -31.4166 | -17.280 | -0.2292 | 0.4372 | 21.389 | 46.7122 |
| Rosiglitazone in DB Period; Metformin in OL Period | -17.0838 | -3.453 | 12.4189 | -16.0971 | 0.215 | 19.6987 |
SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | percent change (Number) | |||||
|---|---|---|---|---|---|---|
| Week 52, GM - SE, n=74, 83 | Week 52, GM, n=74, 83 | Week 52, GM + SE, n=74, 83 | Week 76, GM - SE, n=61, 67 | Week 76, GM, n=61, 67 | Week 76, GM + SE, n=61, 67 | |
| Metformin in DB Period; Metformin in OL Period | 4.3929 | 8.146 | 12.0349 | 4.0983 | 9.846 | 15.9116 |
| Rosiglitazone in DB Period; Metformin in OL Period | 33.2608 | 37.563 | 42.0049 | -0.2973 | 3.137 | 6.6896 |
Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
| Intervention | percent change (Number) | |||||
|---|---|---|---|---|---|---|
| Week 52, GM - SE, n=74, 82 | Week 52, GM, n=74, 82 | Week 52, GM + SE, n=74, 82 | Week 76, GM - SE, n=64, 75 | Week 76, GM, n=64, 75 | Week 76, GM + SE, n=64, 75 | |
| Metformin in DB Period; Metformin in OL Period | -5.8206 | 1.044 | 8.4082 | -8.2870 | -2.932 | 2.7363 |
| Rosiglitazone in DB Period; Metformin in OL Period | 14.1569 | 19.689 | 25.4897 | -12.5441 | -8.156 | -3.5470 |
Free estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Free estrodial is the amount of estrogen available to the body for use. Change was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | 96.1843 | 173.932 | 282.4903 |
| Rosiglitazone in DB Period; Metformin in OL Period | -29.5250 | -3.239 | 32.8525 |
Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | -6.9549 | -3.537 | 0.0073 |
| Rosiglitazone in DB Period; Metformin in OL Period | 3.1109 | 8.993 | 15.2100 |
Free estradiol levels were measured as a percentage of serum estrogen from blood samples. Free estradiol is the amount of estrogen available to the body for use. Percent change was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | -5.4666 | -0.975 | 3.7301 |
| Rosiglitazone in DB Period; Metformin in OL Period | -7.6337 | -2.683 | 2.5337 |
Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | 29.3058 | 50.823 | 75.9217 |
| Rosiglitazone in DB Period; Metformin in OL Period | -15.2056 | 0.513 | 19.1447 |
SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | -3.9036 | -0.825 | 2.3517 |
| Rosiglitazone in DB Period; Metformin in OL Period | -27.0129 | -24.624 | -22.1566 |
Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
| Intervention | percent change (Number) | ||
|---|---|---|---|
| GM - SE | GM | GM + SE | |
| Metformin in DB Period; Metformin in OL Period | -13.9923 | -7.102 | 0.3411 |
| Rosiglitazone in DB Period; Metformin in OL Period | -29.0307 | -24.373 | -19.4104 |
Differences in augmentation index (AI, %) using oscillometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. (NCT03010683)
Timeframe: Baseline, 3 months, 6 months, and 12 months.
| Intervention | percentage of the central pulse pressure (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | |
| Liraglutide | 18 | 15.8 | 13 | 13.9 |
| Metformin | 14 | 13.6 | 15 | 15.3 |
Differences in endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. High PBR values represent reduced glycocalyx thickness. (NCT03010683)
Timeframe: Baseline, 3 months, 6 months, and 12 months.
| Intervention | micrometers (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | |
| Liraglutide | 2.1 | 2.07 | 2.5 | 2.04 |
| Metformin | 2.13 | 2.15 | 2.13 | 2.10 |
Differences in carotid-femoral pulse wave velocity (PWV, m/sec) using tonometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. (NCT03010683)
Timeframe: Baseline, 3 months, 6 months and 12 months
| Intervention | m/s (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | |
| Liraglutide | 11.8 | 11.6 | 10.3 | 10.5 |
| Metformin | 11.2 | 11.5 | 11 | 10.8 |
Association of endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels with pulse wave velocity (PWV, m/sec) at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. (NCT03010683)
Timeframe: Baseline, 3 months, 6 months, and 12 months.
| Intervention | Pearson correlation coefficient (r) (Number) | |||
|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | |
| Liraglutide | 0.39 | 0.36 | 0.32 | 0.44 |
| Metformin | 0.35 | 0.32 | 0.29 | 0.37 |
Percentage of participants achieving A1C < 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 60.3 |
| Saxagliptin 10 mg + Metformin | 59.7 |
| Metformin | 41.1 |
Percentage of participants achieving A1C < 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 60.3 |
| Saxagliptin 10 mg + Metformin | 59.7 |
| Saxagliptin 10 mg | 32.2 |
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 45.3 |
| Saxagliptin 10 mg + Metformin | 40.6 |
| Metformin | 29.0 |
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 45.3 |
| Saxagliptin 10 mg + Metformin | 40.6 |
| Saxagliptin 10 mg | 20.3 |
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 7.5 |
| Saxagliptin 10 mg + Metformin | 5.9 |
| Metformin | 10.1 |
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 7.5 |
| Saxagliptin 10 mg + Metformin | 5.9 |
| Saxagliptin 10 mg | 21.2 |
Mean change from baseline in A1C at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | percent (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Metformin | 9.43 | 7.48 | -1.99 |
| Saxagliptin 10 mg + Metformin | 9.53 | 7.02 | -2.49 |
| Saxagliptin 5 mg + Metformin | 9.41 | 6.93 | -2.53 |
Mean change from baseline in FPG at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Metformin | 199.1 | 152.7 | -47.3 |
| Saxagliptin 10 mg + Metformin | 204.3 | 140.1 | -62.2 |
| Saxagliptin 5 mg + Metformin | 198.9 | 140.2 | -59.8 |
Mean change from baseline in FPG at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Saxagliptin 10 mg | 200.9 | 169.9 | -30.9 |
| Saxagliptin 10 mg + Metformin | 204.3 | 140.1 | -62.2 |
| Saxagliptin 5 mg + Metformin | 198.9 | 140.2 | -59.8 |
Mean change from baseline in A1C at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | percent (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Saxagliptin 10 mg | 9.61 | 7.86 | -1.69 |
| Saxagliptin 10 mg + Metformin | 9.53 | 7.02 | -2.49 |
| Saxagliptin 5 mg + Metformin | 9.41 | 6.93 | -2.53 |
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | mg*min/dL (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Metformin | 57937 | 42428 | -15005 |
| Saxagliptin 10 mg + Metformin | 57219 | 35790 | -21336 |
| Saxagliptin 5 mg + Metformin | 55531 | 35324 | -21080 |
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | mg*min/dL (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Saxagliptin 10 mg | 57584 | 41229 | -16054 |
| Saxagliptin 10 mg + Metformin | 57219 | 35790 | -21336 |
| Saxagliptin 5 mg + Metformin | 55531 | 35324 | -21080 |
Change from baseline at Week 104 is defined as Week 104 minus Week 0. (NCT00103857)
Timeframe: Week 104
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -74.1 |
| Metformin 500 mg b.i.d. | -72.7 |
| Metformin 1000 mg b.i.d. | -86.7 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -96.2 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -110.0 |
| Placebo/Metformin 1000 mg b.i.d. | -93.3 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00103857)
Timeframe: Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -51.9 |
| Metformin 500 mg b.i.d. | -53.4 |
| Metformin 1000 mg b.i.d. | -78.0 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -92.5 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -116.6 |
| Placebo/Metformin 1000 mg b.i.d. | 0.3 |
Change from baseline at Week 54 is defined as Week 54 minus Week 0. (NCT00103857)
Timeframe: Week 54
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -45.9 |
| Metformin 500 mg b.i.d. | -58.6 |
| Metformin 1000 mg b.i.d. | -76.3 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -89.6 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -107.9 |
| Placebo/Metformin 1000 mg b.i.d. | -80.9 |
Change from baseline at Week 104 is defined as Week 104 minus Week 0. (NCT00103857)
Timeframe: Week 104
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -26.8 |
| Metformin 500 mg b.i.d. | -41.4 |
| Metformin 1000 mg b.i.d. | -43.2 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -47.5 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -57.3 |
| Placebo/Metformin 1000 mg b.i.d. | -45.2 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00103857)
Timeframe: Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -17.5 |
| Metformin 500 mg b.i.d. | -27.3 |
| Metformin 1000 mg b.i.d. | -29.3 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -47.1 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -63.9 |
| Placebo/Metformin 1000 mg b.i.d. | 5.8 |
Change from baseline at Week 54 is defined as Week 54 minus Week 0. (NCT00103857)
Timeframe: Week 54
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -16.0 |
| Metformin 500 mg b.i.d. | -29.0 |
| Metformin 1000 mg b.i.d. | -39.6 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -42.5 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -55.6 |
| Placebo/Metformin 1000 mg b.i.d. | -43.9 |
HbA1c is measured as a percent. This change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent. (NCT00103857)
Timeframe: Week 104
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -1.15 |
| Metformin 500 mg b.i.d. | -1.06 |
| Metformin 1000 mg b.i.d. | -1.34 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -1.39 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -1.66 |
| Placebo/Metformin 1000 mg b.i.d. | -1.39 |
HbA1c is measured as a percent. This change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent. (NCT00103857)
Timeframe: Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -0.66 |
| Metformin 500 mg b.i.d. | -0.82 |
| Metformin 1000 mg b.i.d. | -1.13 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -1.40 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -1.90 |
| Placebo/Metformin 1000 mg b.i.d. | 0.17 |
HbA1c is measured as a percent. This change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent. (NCT00103857)
Timeframe: Week 54
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg q.d. | -0.82 |
| Metformin 500 mg b.i.d. | -1.01 |
| Metformin 1000 mg b.i.d. | -1.34 |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -1.41 |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -1.80 |
| Placebo/Metformin 1000 mg b.i.d. | -1.10 |
First phase response from the hyperglycemic clamp (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | nmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 1.68 |
| Glargine Followed by Metformin | 1.68 |
| Placebo | 1.68 |
| Liraglutide + Metformin | 1.68 |
Clamp measure of insulin sensitivity (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | x 10-5 mmol/kg/min per pmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 3.53 |
| Glargine Followed by Metformin | 3.38 |
| Placebo | 3.63 |
| Liraglutide + Metformin | 3.49 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779362)
Timeframe: Secondary analysis was on all participants with a Month 12 visit.
| Intervention | nmol/L (Geometric Mean) | ||
|---|---|---|---|
| ACRPg | Steady State C-peptide | ACRPmax | |
| Glargine Followed by Metformin | 1.88 | 11.6 | 14.1 |
| Liraglutide + Metformin | 2.68 | 21.2 | 10.1 |
| Metformin Alone | 1.93 | 11.7 | 13.4 |
| Placebo | 1.69 | 10.8 | 13.6 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779362)
Timeframe: 3-months after medication washout (Month 15)
| Intervention | nmol/L (Geometric Mean) | |
|---|---|---|
| Steady State C-peptide | ACPRmax | |
| Glargine Followed by Metformin | 3.58 | 4.32 |
| Liraglutide + Metformin | 3.73 | 4.58 |
| Metformin Alone | 3.65 | 4.61 |
| Placebo | 3.60 | 4.45 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication [OAM] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks
| Intervention | percentage of glycosylated hemoglobin (Least Squares Mean) |
|---|---|
| 1.5 mg LY2189265 | -0.78 |
| 0.75 mg LY2189265 | -0.71 |
| Metformin | -0.56 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication [OAM] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate. (NCT01126580)
Timeframe: Baseline, 52 weeks
| Intervention | percentage of glycosylated hemoglobin (Least Squares Mean) |
|---|---|
| 1.5 mg LY2189265 | -0.70 |
| 0.75 mg LY2189265 | -0.55 |
| Metformin | -0.51 |
The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score. (NCT01126580)
Timeframe: 52 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 1.5 mg LY2189265 | 12.92 |
| 0.75 mg LY2189265 | 12.73 |
| Metformin | 12.58 |
Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state. (NCT01126580)
Timeframe: 4 weeks, 13 weeks, 26 weeks, and 52 weeks
| Intervention | nanogram hours per milliliter (ng*hr/mL) (Mean) |
|---|---|
| 1.5 mg LY2189265 | 12036 |
| 0.75 mg LY2189265 | 5919 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01126580)
Timeframe: Baseline through 52 weeks plus 30-day follow up
| Intervention | participants (Number) |
|---|---|
| 1.5 mg LY2189265 | 0 |
| 0.75 mg LY2189265 | 0 |
| Metformin | 0 |
A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The total number of treatment emergent ADA was not analyzed at 26 weeks. (NCT01126580)
Timeframe: Baseline through 52 weeks
| Intervention | participants (Number) |
|---|---|
| 1.5 mg or 0.75 mg LY2189265 | 10 |
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | milliliters of mercury (mmHg) (Least Squares Mean) | |||
|---|---|---|---|---|
| SBP, 26 weeks (n=244, 251, 239) | SBP, 52 weeks (n=221, 219, 215) | DBP, 26 weeks (n=244, 251, 239) | DBP, 52 weeks (n=221, 219, 215) | |
| 0.75 mg LY2189265 | -2.61 | -2.74 | -1.02 | -1.37 |
| 1.5 mg LY2189265 | -1.89 | -0.11 | 0.05 | 0.31 |
| Metformin | -0.91 | -0.98 | -0.64 | -0.38 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline BMI as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | kilograms per meter squared (kg/m^2) (Least Squares Mean) | |
|---|---|---|
| 26 weeks | 52 weeks | |
| 0.75 mg LY2189265 | -0.51 | -0.42 |
| 1.5 mg LY2189265 | -0.86 | -0.73 |
| Metformin | -0.82 | -0.83 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline body weight as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | kilograms (kg) (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=267, 269, 267) | 52 weeks (n=267, 269, 267) | |
| 0.75 mg LY2189265 | -1.36 | -1.09 |
| 1.5 mg LY2189265 | -2.29 | -1.93 |
| Metformin | -2.22 | -2.20 |
The SMBG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (daily mean) were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline daily mean as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | millimoles per liter (mmol/L) (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=195, 200, 211) | 52 weeks (n=197, 200, 212) | |
| 0.75 mg LY2189265 | -1.75 | -1.71 |
| 1.5 mg LY2189265 | -1.98 | -1.99 |
| Metformin | -1.68 | -1.58 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | milliseconds (msec) (Least Squares Mean) | |||
|---|---|---|---|---|
| QTcF interval, 26 weeks (n=230, 237, 221) | QTcF interval, 52 weeks (n=212, 212, 205) | PR interval, 26 weeks (n=226, 235, 218) | PR interval, 52 weeks (n=209, 210, 201) | |
| 0.75 mg LY2189265 | 1.38 | 0.73 | -0.01 | 1.53 |
| 1.5 mg LY2189265 | 2.60 | 3.76 | -0.04 | 1.15 |
| Metformin | -0.91 | -0.53 | -2.04 | -2.88 |
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects and baseline interval as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | beats per minute (bpm) (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=230, 237, 221) | 52 weeks (n=212, 212, 205) | |
| 0.75 mg LY2189265 | 2.57 | 2.36 |
| 1.5 mg LY2189265 | 1.60 | 2.02 |
| Metformin | 0.82 | 1.27 |
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | millimoles per liter (mmol/L) (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=244, 247, 245) | 52 weeks (n=207, 210, 194) | |
| 0.75 mg LY2189265 | -1.46 | -1.00 |
| 1.5 mg LY2189265 | -1.61 | -1.56 |
| Metformin | -1.34 | -1.15 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline HOMA2 as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | percentage of HOMA2 (Least Squares Mean) | |||
|---|---|---|---|---|
| HOMA2-%B, 26 weeks (n=207, 207, 215) | HOMA2-%B, 52 weeks (n=179, 185, 170) | HOMA2-%S, 26 weeks (n=207, 207, 215) | HOMA2-%S, 52 weeks (n=179, 185, 170) | |
| 0.75 mg LY2189265 | 28.96 | 22.5 | 2.71 | 1.84 |
| 1.5 mg LY2189265 | 36.55 | 29.97 | 0.95 | 5.29 |
| Metformin | 14.11 | 9.77 | 9.99 | 10.83 |
Amylase (total and pancreas-derived [PD]) and lipase concentrations were measured. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | units per liter (U/L) (Median) | |||||
|---|---|---|---|---|---|---|
| Amylase (total), 26 weeks | Amylase (total), 52 weeks | Amylase (PD), 26 weeks | Amylase (PD), 52 weeks | Lipase, 26 weeks | Lipase, 52 weeks | |
| 0.75 mg LY2189265 | 6.00 | 5.00 | 4.00 | 3.00 | 5.00 | 5.00 |
| 1.5 mg LY2189265 | 7.00 | 5.50 | 5.00 | 4.00 | 7.00 | 5.00 |
| Metformin | 4.00 | 4.00 | 1.00 | 2.00 | 1.00 | 1.00 |
Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | beats per minute (bpm) (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=244, 251, 239) | 52 weeks (n=221, 219, 215) | |
| 0.75 mg LY2189265 | 2.14 | 1.63 |
| 1.5 mg LY2189265 | 2.39 | 1.84 |
| Metformin | 1.59 | 1.12 |
(NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | picograms per milliliter (pcg/mL) (Median) | |
|---|---|---|
| 26 weeks | 52 weeks | |
| 0.75 mg LY2189265 | 0.00 | 0.00 |
| 1.5 mg LY2189265 | 0.00 | 0.00 |
| Metformin | 0.00 | 0.00 |
"The Diabetes Symptoms Checklist-revised (DSC-r) was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5=extremely to 1=not at all. For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychology-fatigue, psychology-cognitive, neurology-pain, neurology-sensory, cardiology, ophthalmology, hypoglycemia, and hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score." (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=245, 253, 248) | 52 weeks (n=247, 255, 249) | |
| 0.75 mg LY2189265 | -0.16 | 0.42 |
| 1.5 mg LY2189265 | 0.24 | 0.49 |
| Metformin | 0.41 | 0.59 |
The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=244, 249, 241) | 52 weeks (n=245, 251, 244) | |
| 0.75 mg LY2189265 | 1.81 | 1.29 |
| 1.5 mg LY2189265 | 1.93 | 1.82 |
| Metformin | 2.04 | 1.94 |
"The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living [APPADL]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = not at all difficult and 1 = unable to do. The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score." (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=247, 251, 247) | 52 weeks (n=247, 252, 248) | |
| 0.75 mg LY2189265 | 0.19 | -0.05 |
| 1.5 mg LY2189265 | 0.09 | 0.39 |
| Metformin | 0.02 | 0.28 |
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=248, 254, 249) | 52 weeks (n=249, 255, 250) | |
| 0.75 mg LY2189265 | 0.63 | 0.61 |
| 1.5 mg LY2189265 | 0.72 | 0.45 |
| Metformin | 0.79 | 0.75 |
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module. (NCT01126580)
Timeframe: Baseline through 52 weeks plus 30-day follow up
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any CV Event | Any Fatal CV Event | Any Nonfatal CV Event | |
| 0.75 mg LY2189265 | 2 | 0 | 2 |
| 1.5 mg LY2189265 | 1 | 0 | 1 |
| Metformin | 1 | 0 | 1 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01126580)
Timeframe: 26 weeks and 52 weeks
| Intervention | participants (Number) | |
|---|---|---|
| 26 weeks | 52 weeks | |
| 0.75 mg LY2189265 | 150 | 177 |
| 1.5 mg LY2189265 | 163 | 179 |
| Metformin | 151 | 170 |
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter [mg/dL]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01126580)
Timeframe: Baseline through 26 weeks and 52 weeks
| Intervention | events (Number) | |||||
|---|---|---|---|---|---|---|
| Severe, 26 weeks (n=241, 248, 236) | Severe, 52 weeks (n=214, 217, 199) | Documented Symptomatic, 26 weeks (n=241, 248, 236) | Documented Symptomatic, 52 weeks (n=214, 217, 199) | Asymptomatic, 26 weeks (n=241, 248, 236) | Asymptomatic, 52 weeks (n=214, 217, 199) | |
| 0.75 mg LY2189265 | 0 | 0 | 6 | 8 | 9 | 9 |
| 1.5 mg LY2189265 | 0 | 0 | 2 | 7 | 19 | 5 |
| Metformin | 0 | 0 | 2 | 2 | 13 | 9 |
Percent changes in total cholesterol were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | percentage change in total cholesterol (Median) | |
|---|---|---|
| 26 weeks (n=244, 244, 243) | 52 weeks (n=247, 248, 245) | |
| 0.75 mg LY2189265 | -1.77 | -0.78 |
| 1.5 mg LY2189265 | -3.86 | -1.69 |
| Metformin | -3.51 | -3.88 |
Percentage changes in HDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | percentage change in HDL-C (Median) | |
|---|---|---|
| 26 weeks (n=246, 244, 244) | 52 weeks (n=248, 248, 246) | |
| 0.75 mg LY2189265 | 4.20 | 2.31 |
| 1.5 mg LY2189265 | 2.39 | 4.95 |
| Metformin | 5.78 | 4.32 |
Percentage changes in LDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | percentage change in LDL-C (Median) | |
|---|---|---|
| 26 weeks (n=233, 231, 221) | 52 weeks (n=236, 240, 231) | |
| 0.75 mg LY2189265 | -2.70 | -2.34 |
| 1.5 mg LY2189265 | -6.86 | -2.06 |
| Metformin | -8.97 | -7.23 |
Percentage changes in triglycerides were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
| Intervention | percentage change in triglycerides (Median) | |
|---|---|---|
| 26 weeks (n=252, 252, 253) | 52 weeks (n=255, 256, 254) | |
| 0.75 mg LY2189265 | -1.96 | -0.86 |
| 1.5 mg LY2189265 | -2.35 | -4.27 |
| Metformin | 2.56 | 1.91 |
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, prior medication group, and treatment as factors included in the model. (NCT01126580)
Timeframe: 26 weeks and 52 weeks
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| HbA1c less than 7%, 26 weeks | HbA1c less than or equal to 6.5%, 26 weeks | HbA1c less than 7%, 52 weeks | HbA1c less than or equal to 6.5%, 52 weeks | |
| 0.75 mg LY2189265 | 62.6 | 40.0 | 53.2 | 34.7 |
| 1.5 mg LY2189265 | 61.5 | 46.0 | 60.0 | 42.3 |
| Metformin | 53.6 | 29.8 | 48.3 | 28.3 |
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter [mg/dL]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01126580)
Timeframe: Baseline through 52 weeks
| Intervention | events per participant per year (Mean) | ||
|---|---|---|---|
| Severe | Documented Symptomatic | Asymptomatic | |
| 0.75 mg LY2189265 | 0.00 | 0.15 | 0.30 |
| 1.5 mg LY2189265 | 0.00 | 0.62 | 0.24 |
| Metformin | 0.00 | 0.09 | 0.18 |
Suppression of free fatty acids by low dose insulin (i.e., percentage of reduction of plasma FFA with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((plasma FFA without insulin - plasma FFA with insulin infusion)/plasma FFA without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp. (NCT00994682)
Timeframe: 18 months
| Intervention | % of suppression of FFA (Mean) |
|---|---|
| Placebo | 46.1 |
| Pioglitazone | 65.9 |
Suppression of endogenous glucose production (Supp EGP) by low dose insulin (i.e., percentage of reduction of EGP with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((EGP without insulin - EGP with insulin infusion)/EGP without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp. (NCT00994682)
Timeframe: 18 months
| Intervention | % of suppression of EGP (Mean) |
|---|---|
| Placebo | 37.7 |
| Pioglitazone | 55.3 |
Liver fat content was calculated as the fat fraction: 100*(area under the curve [AUC] of fat peak / [AUC of fat peak + AUC of water peak]). (NCT00994682)
Timeframe: 18 months
| Intervention | percentage of fat in liver (Mean) |
|---|---|
| Placebo | 11 |
| Pioglitazone | 7 |
"Number of patients with reduction of at least 2 points in the nonalcoholic fatty liver disease activity score (NAS) (with reduction in at least 2 different histological categories) without worsening of fibrosis. NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3), and ranges from 0-8 .~The scoring system is based on the following grading:~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT00994682)
Timeframe: At 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Pioglitazone | 29 |
Resolution of NASH was defined as absence of NASH after 18 months of therapy in patients with definite NASH (presence of zone 3 accentuation of macrovesicular steatosis of any grade, hepatocellular ballooning of any degree, and lobular inflammatory infiltrates of any amount) at baseline. (NCT00994682)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 10 |
| Pioglitazone | 26 |
Number of patients with osteoporotic fractures (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pioglitazone | 0 |
| Placebo | 0 |
Rate of glucose disappearance (Rd) during high-dose insulin infusion. The rate of plasma glucose disappearance was calculated using Steele's non-steady-state equation. (NCT00994682)
Timeframe: 18 months
| Intervention | mg/kgLBM/min (Mean) |
|---|---|
| Placebo | 5.4 |
| Pioglitazone | 9.6 |
Total body fat measured by dual-energy x-ray absorptiometry (DXA) (NCT00994682)
Timeframe: Months 18
| Intervention | Percentage of body weight that is fat (Mean) |
|---|---|
| Placebo | 36 |
| Pioglitazone | 36 |
(NCT00994682)
Timeframe: Months 18 and 36
| Intervention | kg/m^2 (Mean) | |
|---|---|---|
| BMI Month 18 | BMI Month 36 | |
| Pioglitazone | 34.6 | 35.2 |
| Placebo | 34.6 | 36.7 |
Bone mineral density measured at the levels of spine, femoral neck, hip, and wrist by DXA. (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | g/cm^2 (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Spine BMD at month 18 | Femoral Neck BMD at month 18 | Hip BMD at month 18 | Wrist BMD at month 18 | Spine BMD at month 36 | Femoral Neck BMD at month 36 | Hip BMD at month 36 | Wrist BMD at month 36 | |
| Pioglitazone | 1.04 | 0.84 | 1.05 | 0.76 | 1.06 | 0.84 | 1.02 | 0.75 |
| Placebo | 1.10 | 0.86 | 1.05 | 0.78 | 1.10 | 0.84 | 1.06 | 0.77 |
Homeostatic model assessment of insulin resistance (HOMA-IR) is a method for assessing insulin resistance (IR) from basal fasting plasma glucose (FPG) and fasting plasma insulin (FPI). It is calculated as (FPG x FPI)/405. (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | Arbitrary units (Mean) | |
|---|---|---|
| HOMA-IR month 18 | HOMA-IR month 36 | |
| Pioglitazone | 1.4 | 1.6 |
| Placebo | 4.3 | 2.3 |
"Number of patients with improvement of at least 1 grade in each of the histological parameters.~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal, 1A = Mild, zone 3, perisinusoidal delicate fibrosis; 1B = Moderate, zone 3, perisinusoidal dense fibrosis; 1C = Portal/periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis" (NCT00994682)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | 35 | 25 | 25 | 20 |
| Placebo | 13 | 11 | 12 | 13 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| ALT at month 18 | AST at month 18 | ALT at month 36 | AST at month 36 | |
| Pioglitazone | 27 | 29 | 27 | 27 |
| Placebo | 44 | 38 | 32 | 30 |
Mean change in individual scores compared to baseline. Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis (NCT00994682)
Timeframe: Baseline and Month 18
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | -1.1 | -0.6 | -0.6 | -0.5 |
| Placebo | -0.2 | -0.1 | -0.2 | 0 |
Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis (NCT00994682)
Timeframe: Month 36
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | 0.97 | 0.81 | 0.22 | 0.66 |
| Placebo | 1.56 | 1.30 | 0.33 | 0.89 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | μg/ml (Mean) | |
|---|---|---|
| Adiponectin month 18 | Adiponectin month 36 | |
| Pioglitazone | 22.8 | 24.2 |
| Placebo | 9.1 | 24.0 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | U/L (Mean) | |
|---|---|---|
| CK-18 month 18 | CK-18 month 36 | |
| Pioglitazone | 186 | 151 |
| Placebo | 314 | 245 |
Number of patients developing T2DM and number of patients regressing to NGT among patients with prediabetes (IFG/IGT). (NCT00994682)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Patients developing T2DM | Patients regressing to NGT | |
| Pioglitazone | 1 | 10 |
| Placebo | 2 | 1 |
Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process. (NCT00708175)
Timeframe: Up to 18 months.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 1 |
| Placebo | 3 |
The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray. (NCT00708175)
Timeframe: Baseline and Month 12.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone | -0.69 |
| Placebo | -0.14 |
The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray. (NCT00708175)
Timeframe: Month 12 and Month 18.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone | -0.14 |
| Placebo | 0.04 |
The change between the fasting plasma glucose value collected at each time frame indicated. (NCT00708175)
Timeframe: Baseline and Month 12; Month 12 and Month 18.
| Intervention | mg/dL (Least Squares Mean) | |
|---|---|---|
| Baseline to Month 12 (n=57; n=61) | Month 12 to Month 18 (n=54; n=57) | |
| Pioglitazone | -2.8 | 0.4 |
| Placebo | 6.0 | -1.0 |
Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period. (NCT00708175)
Timeframe: Up to 18 months.
| Intervention | participants (Number) | |
|---|---|---|
| Double-Blind Period (n=76; n=75) | Follow-up Period (n=63; n=59) | |
| Pioglitazone | 1 | 0 |
| Placebo | 7 | 1 |
Fasting Plasma Glucose (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -4.0 |
| Pioglitazone | -10.7 |
Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity. (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | matsuda index (Mean) |
|---|---|
| Placebo | 0.7 |
| Pioglitazone | 3.6 |
Insulin secretion (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | nmol (Mean) |
|---|---|
| Placebo | 35 |
| Pioglitazone | 25 |
carotid intima thickness (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | percentage of intima (Mean) |
|---|---|
| Placebo | 1.7 |
| Pioglitazone | 3.2 |
Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization (NCT00220961)
Timeframe: 2.4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 16.1 |
| Pioglitazone | 5.0 |
Intramyocellular lipid was measured using immunohistochemistry (using oil Red O staining) in muscle biopsy specimens. Oil red O-stained muscle sections were magnified with an Olympus Provis (Tokyo, Japan) light microscope, and images were digitally captured by using a connected charge-coupled device camera (Sony, Tokyo, Japan). Fiber-typed and oil red O-stained fibers were matched. The oil red O staining intensity of either type 1 or 2 muscle fibers was quantified using National Institutes of Health Image program (http://rsb.info.nih.gov/nih-image/). By adjusting a density threshold, the software was set to recognize the presence of one fat droplet only if its highlighted surface was exceeding 0.40 μm2 or larger. Muscle lipid content was calculated by total area of lipid droplets in a given muscle fiber divided by the total area of the same fiber. The mean number of fibers analyzed per sample was 40 for type 1 and 2 muscle fibers (NCT00470262)
Timeframe: 3 months
| Intervention | % of lipid area stained (Mean) | |
|---|---|---|
| pre | post | |
| Fenofibrate 145mg PO QD | 3.67 | 3.46 |
| Fenofibrate 145mg PO QD + Pioglitazone 45mg PO BID | 5.32 | 2.82 |
Insulin sensitivity was measure through frequently sampled intravenous glucose tolerance test. Subjects presented to research center fasting. Blood samples were collected at -21, -11, and -1 minutes. At time t=0 initiates the start of the IVGTT and the injection of glucose into the non-sampling arm. The glucose dose was calculated as 11.4g/m2 of body surface area, given as a 50% dextrose solution. This glucose injection was administered over 60 seconds or less. At time t=20 minutes, an insulin dose of 0.04u/kg was administered over 30 seconds. Blood samples were collected at times t=2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 40, 50, 70, 90, 100, 120, 140, 160, and 180. If blood sugar did not return to a steady state the test was continued to t= 210 or t= 240. (NCT00470262)
Timeframe: 3 months
| Intervention | mg*kg^-1*min^-1 (Mean) | |
|---|---|---|
| pre | post | |
| Fenofibrate 145 mg PO QD + Pioglitazone | 1.73 | 2.93 |
| Fenofibrate 145mg PO QD | 1.48 | 1.89 |
HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20) and Week 44
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Phase 2: Metformin + Sitagliptin + Glimepiride | -0.65 |
| Phase 2: Metformin + Sitagliptin + Repaglinide | -0.62 |
| Phase 2: Metformin + Sitagliptin + Acarbose | -0.46 |
| Phase 2: Metformin + Sitagliptin + Gliclazide | -0.69 |
Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20), Week 44
| Intervention | kg (Mean) |
|---|---|
| Phase 2: Metformin + Sitagliptin + Glimepiride | 0.4 |
| Phase 2: Metformin + Sitagliptin + Repaglinide | 0.2 |
| Phase 2: Metformin + Sitagliptin + Acarbose | -0.9 |
| Phase 2: Metformin + Sitagliptin + Gliclazide | 0.2 |
"The percentage of participants with a GI AE of nausea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44
| Intervention | Percentage of Participants (Number) |
|---|---|
| Phase 2: Metformin + Sitagliptin + Glimepiride | 0 |
| Phase 2: Metformin + Sitagliptin + Repaglinide | 0 |
| Phase 2: Metformin + Sitagliptin + Acarbose | 0.4 |
| Phase 2: Metformin + Sitagliptin + Gliclazide | 0.2 |
"The percentage of participants with a GI AE of abdominal pain was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44
| Intervention | Percentage of Participants (Number) |
|---|---|
| Phase 2: Metformin + Sitagliptin + Glimepiride | 0 |
| Phase 2: Metformin + Sitagliptin + Repaglinide | 0 |
| Phase 2: Metformin + Sitagliptin + Acarbose | 0.4 |
| Phase 2: Metformin + Sitagliptin + Gliclazide | 0.2 |
"The percentage of participants with a GI AE of diarrhea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44
| Intervention | Percentage of Participants (Number) |
|---|---|
| Phase 2: Metformin + Sitagliptin + Glimepiride | 0.5 |
| Phase 2: Metformin + Sitagliptin + Repaglinide | 0.4 |
| Phase 2: Metformin + Sitagliptin + Acarbose | 0.4 |
| Phase 2: Metformin + Sitagliptin + Gliclazide | 0.9 |
"The percentage of participants with a GI AE of vomiting was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44
| Intervention | Percentage of Participants (Number) |
|---|---|
| Phase 2: Metformin + Sitagliptin + Glimepiride | 0.2 |
| Phase 2: Metformin + Sitagliptin + Repaglinide | 0 |
| Phase 2: Metformin + Sitagliptin + Acarbose | 0.2 |
| Phase 2: Metformin + Sitagliptin + Gliclazide | 0.2 |
Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported. (NCT01709305)
Timeframe: From Week 20 through Week 44
| Intervention | Percentage of Participants (Number) |
|---|---|
| Phase 2: Metformin + Sitagliptin + Glimepiride | 8.9 |
| Phase 2: Metformin + Sitagliptin + Repaglinide | 6.1 |
| Phase 2: Metformin + Sitagliptin + Acarbose | 0.5 |
| Phase 2: Metformin + Sitagliptin + Gliclazide | 3.6 |
The number of subjects having a change in Alanine Aminotransferase (ALAT) from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management. (NCT00819741)
Timeframe: Week -2, week 16
| Intervention | Subjects (Number) |
|---|---|
| Repaglinide + Metformin | 4 |
| Repaglinide | 5 |
The number of subjects having a change in Aspartate Aminotransferase (ASAT) from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management. (NCT00819741)
Timeframe: Week -2, week 16
| Intervention | Subjects (Number) |
|---|---|
| Repaglinide + Metformin | 2 |
| Repaglinide | 4 |
Calculated as an estimate of the mean change in 2-hour postprandial plasma glucose following a standard test meal after 16 weeks of treatment (NCT00819741)
Timeframe: Week 0, week 16
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Repaglinide + Metformin | -7.525 |
| Repaglinide | -6.794 |
Calculated as an estimate of the mean change in 2-hour postprandial serum C-peptide after 16 weeks of treatment (NCT00819741)
Timeframe: Week 0, week 16
| Intervention | ng/ml (Least Squares Mean) |
|---|---|
| Repaglinide + Metformin | 2.301 |
| Repaglinide | 2.081 |
Calculated as an estimate of the mean change in 2-hour postprandial serum insulin after 16 weeks of treatment. (NCT00819741)
Timeframe: Week 0, week 16
| Intervention | mU/L (Least Squares Mean) |
|---|---|
| Repaglinide + Metformin | 34.083 |
| Repaglinide | 28.548 |
Calculated as an estimate of the mean change in fasting plasma glucose after 16 weeks of treatment. (NCT00819741)
Timeframe: week 0, week 16
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Repaglinide + Metformin | -4.646 |
| Repaglinide | -3.982 |
Calculated as an estimate of the mean change in fasting serum C-peptide after 16 weeks of treatment (NCT00819741)
Timeframe: Week 0, week 16
| Intervention | ng/ml (Least Squares Mean) |
|---|---|
| Repaglinide + Metformin | 0.041 |
| Repaglinide | 0.405 |
Calculated as an estimate of the mean change in fasting serum insulin after 16 weeks of treatment. (NCT00819741)
Timeframe: Week 0, week 16
| Intervention | mU/L (Least Squares Mean) |
|---|---|
| Repaglinide + Metformin | 3.163 |
| Repaglinide | 5.694 |
Calculated as an estimate of the mean change in HbA1c after 16 weeks of treatment. (NCT00819741)
Timeframe: week -2 (screening), week 16
| Intervention | percentage (%) of total haemoglobin (Least Squares Mean) |
|---|---|
| Repaglinide + Metformin | -4.450 |
| Repaglinide | -4.148 |
The number of subjects having a electrocardiogram (ECG) that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management. (NCT00819741)
Timeframe: Week -2, week 16
| Intervention | Subjects (Number) |
|---|---|
| Repaglinide + Metformin | 3 |
| Repaglinide | 2 |
Haemoglobin was measured. The number of subjects having a change in Haemoglobin measurement from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant' 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management. (NCT00819741)
Timeframe: Week -2, week 16
| Intervention | Subjects (Number) |
|---|---|
| Repaglinide + Metformin | 1 |
| Repaglinide | 0 |
The number of subjects having a physical examination event that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. Physical examination included cardiovascular system, respiratory system, musculoskeletal system, nervous system and abdomen. (NCT00819741)
Timeframe: Week -2, week 16
| Intervention | Subjects (Number) |
|---|---|
| Repaglinide + Metformin | 3 |
| Repaglinide | 0 |
Calculated as an estimate of the mean change in 7-point (before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, bedtime) plasma glucose profile after 16 weeks of treatment. (NCT00819741)
Timeframe: Week 0, week 16
| Intervention | mmol/L (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Before breakfast, N=204, 199 | 2 hours after breakfast, N=206, 201 | Before lunch, N=203, 200 | 2 hours after lunch, N=204, 201 | Before dinner N=204, 202 | 2 hours after dinner N=204, 199 | Bedtime N=195, 188 | Average N=207, 202 | |
| Repaglinide | -4.58 | -7.40 | -6.28 | -6.98 | -5.09 | -5.70 | -5.82 | -5.99 |
| Repaglinide + Metformin | -4.99 | -7.85 | -6.85 | -8.00 | -5.62 | -7.13 | -6.93 | -6.78 |
Calculated as the mean change in diastolic and systolic blood pressure after 16 weeks of treatment (NCT00819741)
Timeframe: Week 0, week 16
| Intervention | mmHg (Mean) | |
|---|---|---|
| Blood pressure diastolic | Blood pressure systolic | |
| Repaglinide | -0.9 | -1.4 |
| Repaglinide + Metformin | -1.0 | -1.5 |
Number of hypoglycaemic episodes from Week 0 to Week 16, defined as major, minor or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00819741)
Timeframe: Weeks 0-16
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Repaglinide | 0 | 16 | 71 |
| Repaglinide + Metformin | 0 | 41 | 90 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
63 reviews available for carbamates and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2 | 2020 |
Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.
Topics: Carbamates; Cause of Death; Cognition Disorders; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypog | 2017 |
Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Topics: Algorithms; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, | 2013 |
The pharmacogenetics of type 2 diabetes: a systematic review.
Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; | 2014 |
Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials.
Topics: Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypog | 2014 |
Pharmacogenomics of glinides.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inactivation, Meta | 2015 |
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type | 2015 |
Drugs for type 2 diabetes.
Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinati | 2008 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hyp | 2009 |
Advances in oral therapy for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; | 2000 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe | 2012 |
Repaglinide: a review of its use in type 2 diabetes mellitus.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines; Randomized Controll | 2012 |
Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.
Topics: Aged; Azepines; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hyp | 2012 |
Insulin secretagogues.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hyp | 2002 |
[Repaglinide (NN-623)].
Topics: Adenosine Triphosphate; Administration, Oral; Calcium Channels; Carbamates; Clinical Trials as Topic | 2002 |
Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes.
Topics: Carbamates; Circadian Rhythm; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insul | 2002 |
Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
Topics: Area Under Curve; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucose; Humans; Hyperglycem | 2002 |
The impact of prandial glucose regulation in practice.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hy | 2002 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Age | 2002 |
[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agent | 2003 |
Treating diabetes using oral agents.
Topics: Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosamine; | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diab | 2003 |
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cost of Illness; Cost-Benefit Analysis; | 2004 |
Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agent | 2003 |
Meglitinide analogues for type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metfor | 2007 |
New oral agents for type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone | 2007 |
Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Topics: Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adver | 2007 |
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2008 |
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mel | 1996 |
[Repaglinide (NN-623)].
Topics: Animals; Blood Glucose; Carbamates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; G | 1997 |
Repaglinide.
Topics: Animals; Carbamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glyburide; Humans; | 1998 |
Type 2 diabetes: glycemic targets and oral therapies for older patients.
Topics: 1-Deoxynojirimycin; Acarbose; Age Factors; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type | 1998 |
Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Clinical Trials as Topic; Diabetes Mellitu | 1998 |
The elderly Type 2 diabetic patient: special considerations.
Topics: Aged; Amyloid; Blood Glucose; Carbamates; Cognition Disorders; Depression; Diabetes Mellitus, Type 2 | 1998 |
Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies.
Topics: Administration, Oral; Animals; Carbamates; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Piperidin | 1999 |
Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Pipe | 1999 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Acarbose; Administration, Oral; Algorithms; Carbamates; Chromans; Diabetes Mellitus, Type 2; Evidenc | 1999 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Acarbose; Administration, Oral; Algorithms; Carbamates; Chromans; Diabetes Mellitus, Type 2; Evidenc | 1999 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Acarbose; Administration, Oral; Algorithms; Carbamates; Chromans; Diabetes Mellitus, Type 2; Evidenc | 1999 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Acarbose; Administration, Oral; Algorithms; Carbamates; Chromans; Diabetes Mellitus, Type 2; Evidenc | 1999 |
Repaglinide as monotherapy in Type 2 diabetes.
Topics: Blood Glucose; Carbamates; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Food; Gly | 1999 |
Preclinical and clinical studies on safety and tolerability of repaglinide.
Topics: Aged; Animals; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Pip | 1999 |
The use of insulin secretagogues in the treatment of type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Gluc | 1999 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 1999 |
Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Feeding Behavior; Humans | 1999 |
New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Piperidines | 1999 |
New agents for Type 2 diabetes.
Topics: Anti-Obesity Agents; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglyce | 1999 |
Combining sulfonylureas and other oral agents.
Topics: Acarbose; Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2000 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; | 2000 |
Pharmacology and clinical experience with repaglinide.
Topics: Animals; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Eating; Humans; Hypoglycem | 2000 |
Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Humans; Hyp | 2000 |
The importance of early insulin secretion and its impact on glycaemic regulation.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Humans; Hyp | 2000 |
Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Age | 2000 |
The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Patient Compliance | 2001 |
Combination therapy in type 2 diabetes: the role of repaglinide.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Humans; | 2001 |
A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
Topics: Blood Glucose; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2000 |
Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Topics: Animals; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hypoglyce | 2001 |
[Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
Topics: Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; H | 2001 |
[Objectives and therapeutic strategy in type 2 diabetes mellitus].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic | 2001 |
Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Aging; Animals; Biological Availability; Blood Glucose; Carbamate | 2001 |
Insulinotropic meglitinide analogues.
Topics: Adult; Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2001 |
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
Topics: Administration, Oral; Biguanides; Blood Glucose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Di | 2002 |
Type 2 diabetes management: a comprehensive clinical review of oral medications.
Topics: Benzamides; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase In | 2002 |
Current oral agents for type 2 diabetes. Many options, but which to choose when?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Gly | 2002 |
Clinical pharmacokinetics and pharmacodynamics of repaglinide.
Topics: Adult; Aged; Blood Glucose; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Re | 2002 |
102 trials available for carbamates and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Cross-Over Studies; Diabetes Mellitus, Typ | 2020 |
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycat | 2020 |
A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide.
Topics: Acarbose; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypogly | 2020 |
Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Carbamates; Cross-Over Studies; Diabet | 2017 |
Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Carbamates; Child; Cystic Fibrosis; Diabetes Mellitus, | 2018 |
A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus.
Topics: Asian People; Blood Glucose; Carbamates; Cytochrome P-450 CYP2C8; Diabetes Mellitus, Type 2; Female; | 2018 |
Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; F | 2019 |
Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.
Topics: Actins; Adult; Aged; Aged, 80 and over; Antigens; Blood Glucose; Carbamates; Diabetes Mellitus, Type | 2018 |
Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus.
Topics: Adaptor Proteins, Signal Transducing; Adult; Alleles; Asian People; Blood Glucose; Carbamates; Case- | 2014 |
Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response | 2014 |
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Topics: Body Mass Index; Carbamates; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diab | 2014 |
Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administrati | 2014 |
PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus.
Topics: Adult; Asian People; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Ins | 2015 |
Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gl | 2016 |
Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combina | 2016 |
A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients.
Topics: Adult; Asian People; Carbamates; China; Diabetes Mellitus, Type 2; Female; Hep G2 Cells; Humans; Ins | 2016 |
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2017 |
Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Topics: Aged; Apolipoproteins; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Cross-Over Studies; Diabet | 2009 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hyp | 2009 |
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Topics: Acarbose; Administration, Oral; Adult; Blood Glucose; Carbamates; Cross-Over Studies; Diabetes Melli | 2009 |
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
Topics: Acarbose; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; G | 2009 |
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, | 2009 |
Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Ther | 2009 |
Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated He | 2009 |
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination | 2009 |
KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes.
Topics: Adult; Alleles; Amino Acid Substitution; Asian People; Blood Glucose; Carbamates; Diabetes Mellitus, | 2010 |
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Carbamates; Chi-Square Distribution; Diabetes Mell | 2010 |
Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus.
Topics: Adult; Aged; Benzamides; Blood Glucose; Body Mass Index; C-Peptide; Carbamates; Cross-Over Studies; | 2010 |
Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Cross-Over Studies; Diabetes Mell | 2010 |
Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Fe | 2011 |
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes.
Topics: Carbamates; Confidence Intervals; Deoxyglucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agen | 2011 |
Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Alleles; Asian People; Blood Glucose; Carbamates; China; Diabetes Melli | 2011 |
Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Topics: Adult; Blood Glucose; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazid | 2011 |
Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
Topics: Adolescent; Adult; Aged; Blood Glucose; Carbamates; China; Diabetes Mellitus, Type 2; Drug Therapy, | 2011 |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; | 2011 |
NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.
Topics: Adult; Aged; Alleles; Asian People; Basic Helix-Loop-Helix Transcription Factors; Blood Glucose; Car | 2012 |
Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.
Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Brachial Artery; Carbamates; Diabetes Mellitu | 2012 |
KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients.
Topics: Adult; Asian People; Carbamates; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genotype; Humans | 2012 |
Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China.
Topics: Carbamates; Cation Transport Proteins; China; Diabetes Mellitus, Type 2; Female; Gene Frequency; Hum | 2012 |
Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues.
Topics: Aged; Arrhythmias, Cardiac; Carbamates; Diabetes Mellitus, Type 2; Electrocardiography; Exercise Tes | 2014 |
Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
Topics: Aged; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Female | 2002 |
Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
Topics: Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Fasting; Feeding Behavior; Female; Fructosamine; | 2002 |
Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy.
Topics: Blood Glucose; Carbamates; Creatinine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug | 2002 |
The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.
Topics: Carbamates; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; | 2003 |
Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; | 2003 |
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Topics: Blood Glucose; Blood Pressure; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Female; H | 2003 |
Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin.
Topics: Blood Glucose; Carbamates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypog | 2003 |
The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study.
Topics: Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Health Status; Health Status Indicators; | 2003 |
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Topics: Area Under Curve; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, | 2003 |
Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus.
Topics: Analysis of Variance; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; | 2003 |
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2003 |
Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, | 2004 |
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Diabetes Mellitus, Type | 2004 |
Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasti | 2004 |
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated He | 2004 |
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Topics: Biomarkers; Body Mass Index; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Ex | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
Topics: Adult; Aged; C-Peptide; Carbamates; Cohort Studies; Cross-Over Studies; Diabetes Mellitus, Type 2; D | 2004 |
Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Topics: Acarbose; Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Cross-Over Studies; Diabetes Mellitus, | 2004 |
The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.
Topics: Administration, Oral; Adult; Aged; Brachial Artery; Carbamates; Combined Modality Therapy; Diabetes | 2004 |
The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Carbamates; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasti | 2004 |
Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.
Topics: Adult; Aged; Blood Glucose; Blood Specimen Collection; Carbamates; Diabetes Mellitus, Type 2; Drug A | 2004 |
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.
Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucag | 2005 |
Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Brachial Artery; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Dia | 2005 |
Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Type 2; D | 2005 |
[Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Topics: Adult; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fema | 2005 |
Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Ea | 2005 |
Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin.
Topics: Adult; Blood Glucose; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Sc | 2005 |
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Topics: Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Carbamates; Cardiovascular Diseases; Cross | 2005 |
Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Carbamates; Cross-Over Studies; Diabetes Mellitus, | 2005 |
Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Topics: Adenosine Diphosphate; Blood Glucose; C-Reactive Protein; Carbamates; Cross-Over Studies; Diabetes M | 2006 |
An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
Topics: Adult; Aged; Blood Glucose; Carbamates; Ceremonial Behavior; Diabetes Mellitus, Type 2; Fasting; Fem | 2006 |
Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial.
Topics: Aged; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Glyburide; Humans; Piperidines | 2006 |
Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.
Topics: Angina Pectoris; Carbamates; Diabetes Mellitus, Type 2; Electrocardiography; Exercise Test; Female; | 2007 |
Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment.
Topics: Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Admin | 2006 |
Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion.
Topics: Carbamates; Diabetes Mellitus, Type 2; Diazoxide; Dose-Response Relationship, Drug; Female; Humans; | 2007 |
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
Topics: Adiponectin; Biomarkers; Blood Glucose; Body Weight; C-Peptide; C-Reactive Protein; Carbamates; Cros | 2007 |
A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; | 2007 |
Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
Topics: Adult; Age of Onset; Aged; Area Under Curve; Asian People; Blood Glucose; Carbamates; China; Cyclohe | 2007 |
Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Drug Ad | 2008 |
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; Carbamates; Cholesterol; Cholesterol, LDL; Cross-Over Studies | 2008 |
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabeti | 2008 |
Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glybur | 1993 |
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mel | 1996 |
A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
Topics: Adult; Aged; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemi | 1998 |
A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; G | 1999 |
A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Meth | 1999 |
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Topics: Australia; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Di | 1999 |
Repaglinide versus glyburide: a one-year comparison trial.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; | 1999 |
A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans | 1999 |
Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; Eating; F | 1999 |
Repaglinide in combination therapy with metformin in Type 2 diabetes.
Topics: Australia; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemogl | 1999 |
Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
Topics: Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2000 |
Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Topics: Administration, Oral; Area Under Curve; Blood Glucose; C-Peptide; Carbamates; Cohort Studies; Cross- | 2000 |
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Chromans; Cross-Over Studies; Diabetes Mellitus, | 2000 |
Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; | 2001 |
Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.
Topics: Aged; Analysis of Variance; Area Under Curve; Carbamates; Diabetes Mellitus, Type 2; Dose-Response R | 2001 |
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2001 |
Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Doubl | 1999 |
Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ad | 2001 |
Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Humans; Hypoglyce | 2002 |
Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Neu | 2002 |
104 other studies available for carbamates and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Clinical Effects of Exercise Rehabilitation Combined with Repaglinide in the Treatment of Diabetes.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines; Retrospective Studi | 2022 |
Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals.
Topics: Acarbose; Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hypergl | 2020 |
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Genotype; Hepaci | 2021 |
Repaglinide and Metformin-Loaded Amberlite Resin-Based Floating Microspheres for the Effective Management of Type 2 Diabetes.
Topics: Animals; Carbamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Metformin; Mice; Mi | 2021 |
Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency.
Topics: Aged; Blood Glucose; Carbamates; Clopidogrel; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypog | 2021 |
Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
Topics: Aged; Benzamides; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Di | 2021 |
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors | 2022 |
Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
Topics: Aged; Carbamates; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug Uti | 2017 |
The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Graves Ophthalmopathy; Humans; H | 2018 |
A low GLP-1 response among patients treated for acute organophosphate and carbamate poisoning: a comparative cross-sectional study from an agrarian region of Sri Lanka.
Topics: Acetylcholinesterase; Acute Disease; Adult; Atropine; Carbamates; Chronic Disease; Cross-Sectional S | 2019 |
Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management.
Topics: Aged; Aged, 80 and over; Aging; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2018 |
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2019 |
A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients.
Topics: Alleles; Asian People; Carbamates; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Genotype | 2019 |
Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Topics: Antiviral Agents; Blood Glucose; Carbamates; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dru | 2020 |
Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.
Topics: Aged; Carbamates; Diabetes Mellitus, Type 2; Humans; Male; Piperidines; Thrombocytopenia | 2013 |
Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors.
Topics: Amidohydrolases; Animals; Blood Glucose; Brain; Carbamates; Diabetes Mellitus, Type 2; Diabetic Neur | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Thera | 2014 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2015 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus.
Topics: Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Frail Elderly; Humans; Hypoglycemia; Hypog | 2014 |
[New medications for patients with type 2 diabetes].
Topics: Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination | 2014 |
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular | 2015 |
Comments on "Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials".
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Piperidines | 2015 |
Getting to goal in newly diagnosed type 2 diabetes using combination drug "subtraction therapy".
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2015 |
Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients.
Topics: Administration, Oral; Adult; Alleles; Asian People; Blood Glucose; Body Mass Index; Carbamates; Chin | 2016 |
α/β-Hydrolase Domain 6 Deletion Induces Adipose Browning and Prevents Obesity and Type 2 Diabetes.
Topics: 3T3-L1 Cells; Adipose Tissue, Brown; Animals; Biphenyl Compounds; Carbamates; Diabetes Mellitus, Typ | 2016 |
Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin.
Topics: Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Huma | 2016 |
Clinical and molecular characterization of a novel INS mutation identified in patients with MODY phenotype.
Topics: Adolescent; Animals; Carbamates; Child; Diabetes Mellitus, Type 2; Female; Heterozygote; High-Throug | 2016 |
Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
Topics: Acarbose; Administration, Oral; Age Factors; Aged; Carbamates; Cohort Studies; Confidence Intervals; | 2017 |
Estimation of ellagic acid and/or repaglinide effects on insulin signaling, oxidative stress, and inflammatory mediators of liver, pancreas, adipose tissue, and brain in insulin resistant/type 2 diabetic rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Brain; Carbamates; Diabetes Melli | 2017 |
Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Topics: Area Under Curve; Carbamates; Cyclohexanes; Databases, Factual; Diabetes Mellitus, Type 2; Drug Inte | 2017 |
Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.
Topics: ATP-Binding Cassette Transporters; Carbamates; Diabetes Mellitus, Type 2; DNA; Female; Gene Frequenc | 2008 |
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
Topics: Area Under Curve; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Hy | 2008 |
Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Topics: Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Blood Pressure; Carbamates; Diabetes Mell | 2009 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cy | 2009 |
Metformin/Repaglinide (PrandiMet) for type 2 diabetes.
Topics: Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; G | 2009 |
Change in glucometer settings as a cause of sudden deterioration of glycemic control in type 2 diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Computers; Diabetes Mellitus, Type 2; Equi | 2009 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Ag | 2009 |
Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies.
Topics: Animals; Bile; Biotransformation; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inh | 2010 |
Diabetes under control: Understanding oral antidiabetic agents.
Topics: Administration, Oral; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2010 |
A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.
Topics: Adaptor Proteins, Signal Transducing; Carbamates; China; Diabetes Mellitus, Type 2; Female; Humans; | 2010 |
IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.
Topics: Adult; Aged; Asian People; Carbamates; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gene | 2010 |
Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.
Topics: Adult; Aged; Base Sequence; Carbamates; Case-Control Studies; Cation Transport Proteins; China; Diab | 2010 |
Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Chemistry, Pharmaceutical; Delayed-Action | 2009 |
Hypersensitivity to repaglinide.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Erythema; Exanthema; Hum | 2011 |
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Alleles; Asian People; Carbamates; Cholesterol; Control Groups; Diabetes Mellitus, Type | 2011 |
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Carbamates; Diabetes Mellitus, Type 2; Drug T | 2011 |
Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes.
Topics: Adult; Aged; Alleles; Asian People; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; DNA Primer | 2012 |
Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.
Topics: Acidosis, Lactic; Aged; Carbamates; Consensus Development Conferences as Topic; Contraindications; D | 2012 |
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.
Topics: Adamantane; Aged; Carbamates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hy | 2013 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic | 2002 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Topics: Carbamates; Cohort Studies; Decision Trees; Diabetes Mellitus, Type 2; Direct Service Costs; Drug Co | 2003 |
A comparison of costs for four oral antidiabetic regimens within a managed care population.
Topics: Administration, Oral; Adolescent; Adult; Aged; California; Carbamates; Cohort Studies; Data Interpre | 2003 |
[Type 2 diabetes mellitus pathogenesis: new therapeutic managements?].
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ins | 2003 |
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
Topics: Adiponectin; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2003 |
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; | 2003 |
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.
Topics: Antihypertensive Agents; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Diabetes Mellitus | 2004 |
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Topics: Carbamates; Cohort Studies; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cyclohexane | 2004 |
Continuous glucose monitoring: physiologic and pathophysiologic significance.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Circadian R | 2004 |
Acute hepatotoxicity caused by repaglinide.
Topics: Aged; Carbamates; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypergl | 2004 |
Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Eating; Humans; H | 2004 |
Accuracy of continuous nocturnal glucose screening after 48 and 72 hours in type 2 diabetes patients on combined oral and insulin therapy.
Topics: Administration, Oral; Aged; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2004 |
Cholestatic hepatitis associated with repaglinide.
Topics: Aged; Carbamates; Chemical and Drug Induced Liver Injury; Cholestasis; Diabetes Mellitus, Type 2; Hu | 2005 |
Mild, reversible pancytopenia induced by rosiglitazone.
Topics: Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents | 2005 |
Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Topics: Acarbose; Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gl | 2005 |
Oral agents in managing diabetes mellitus in children and adolescents.
Topics: Administration, Oral; Adolescent; Carbamates; Child; Clinical Trials as Topic; Diabetes Mellitus, Ty | 2005 |
Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.
Topics: Aged; Carbamates; Cause of Death; Cohort Studies; Diabetes Mellitus, Type 2; Drug Prescriptions; Eng | 2006 |
A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.
Topics: Adult; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Fasting; Female; Fructosamine; Glycat | 2007 |
Use of repaglinide during the first weeks of pregnancy in two type 2 diabetic women.
Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Piperidines; Pregnancy; Pregn | 2006 |
Use of repaglinide on a pregnant woman during embryogenesis.
Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Embryonic Development; Female; Humans; Hypoglycemic Ag | 2007 |
Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets.
Topics: Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; H | 2008 |
Severe hypoglycemia from clarithromycin-repaglinide drug interaction.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Blood Glucose; Carbamates; Clarithromycin; Diabetes Mellit | 2008 |
Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Fasting; Female | 1997 |
Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
Topics: Animals; Binding Sites; Binding, Competitive; Blood Glucose; Carbamates; Cohort Studies; Culture Tec | 1998 |
Repaglinide for type 2 diabetes mellitus.
Topics: Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; F | 1998 |
Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Experimental; Diabetes | 1998 |
Drug knowledge is critical.
Topics: Aged; Carbamates; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemia; Hypoglycemic A | 1998 |
For diabetes: a preprandial pill ...
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines | 1998 |
[Flexible oral therapy of diabetes mellitus type 2: dietary glucose regulation as therapeutic principle. 34th annual session of the European Association for the Study of Diabetes (EASD). Barcelona, 8-12 September 1998].
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Diet, Diabetic; Glucose; | 1998 |
Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
Topics: Aged; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Piperidines | 1999 |
Improving management of type 2 diabetes mellitus: 4. Meglitinides.
Topics: Carbamates; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines | 1999 |
Comments on type 2 diabetes screening and treatment.
Topics: Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedul | 2000 |
Managing type 2 diabetes. A look at the newer agents.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; P | 1999 |
[Mechanisms of action of repaglinide at a cellular level].
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Inulin; Piperidin | 1999 |
[Insulin secretion and repaglinide].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Diabetic; Exercise; Humans; Hypo | 1999 |
[Repaglinide in combination therapy in type 2 diabetes].
Topics: Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insul | 1999 |
Repaglinide: a novel oral antidiabetic agent.
Topics: Administration, Oral; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Type 2; Humans; Hyp | 2000 |
[Prandial glucose regulator for type 2 diabetic patients. Beta cells produce insulin according to need].
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Islets o | 1999 |
[Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
Topics: Blood Glucose; Carbamates; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 2000 |
Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
Topics: Attitude to Health; Blood Glucose; Carbamates; Cohort Studies; Diabetes Mellitus, Type 2; Drug Thera | 2000 |
Honing type 2 diabetes treatment.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiaz | 2001 |
Insulin secretagogues.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistanc | 1997 |
[Large general practice study with repaglinide. Fewer "anxiety eating" in diabetic patients].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diet, Diabetic; Feeding Behavior; Humans; Hypoglycemic Agents | 2001 |
[Repaglinide].
Topics: Carbamates; Diabetes Mellitus, Type 2; Half-Life; Humans; Hypoglycemic Agents; Insulin; Piperidines; | 2001 |
A new era in type 2 diabetes mellitus treatment?
Topics: 1-Deoxynojirimycin; Acarbose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycem | 2001 |
Repaglinide dose response? A clinician's viewpoint.
Topics: Blood Glucose; C-Peptide; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; H | 2000 |
Utilization of oral hypoglycemic agents in a drug-insured U.S. population.
Topics: Carbamates; Chromans; Cohort Studies; Databases as Topic; Diabetes Mellitus, Type 2; Enzyme Inhibito | 2001 |
Repaglinide dose response? A clinician's viewpoint.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exercise; Hu | 1999 |
The importance of rapid insulin secretion: revisited.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Homeostasis; Humans; Hypoglycemic Agents; Insu | 1999 |
[Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)].
Topics: Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Human | 2001 |
Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.
Topics: Anti-Infective Agents; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Age | 2001 |
Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Human | 2001 |
[Therapy of type 2 diabetes. Avoiding postprandial blood glucose peaks!].
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Piperidi | 2001 |
Type 2 diabetes management.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic | 2002 |